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Summary 
 
We observed a declining trend in malaria transmission at Nouna, 
Burkina Faso during the rainy season from 2009-2011. Single and mixed 
infections for Plasmodium falciparum and Plasmodium malariae were 
significantly reduced compared to the baseline data (rainy season 2000) and 
a lower prevalence of P. malariae was associated with a reduced 
transmission intensity. Microscopic examination has a lower detection limit 
and is associated with under-estimation of parasite burden, which 
suggested the use of molecular diagnosis such as PCR as a more sensitive 
method in determining the prevalence of malaria infections.   
 
 Amodiaquine (AQ) is an antimalarial compound chemically and 
functionally related to chloroquine (CQ). Currently, it is used in combination 
with artesunate (AS) as the first choice to treat uncomplicated P. falciparum 
malaria in some countries in Africa and South America. Chloroquine-
resistant parasites and cross-resistance between CQ and AQ or its active 
metabolite Desethyl-amodiaquine (DQ) have been observed  in Burkina 
Faso. pfcrt and pfmdr1 are genes genetically associated with the resistance 
mechanism and the underlying mechanisms for cross-resistance are still 
under debate. The main aim of this study was to assess the susceptibility 
patterns of clonal field isolates P. falciparum compared to reference 
laboratory strains (Dd2 and HB3). Blood samples from 402 patients from the 
village Bourasso, Nouna, Burkina Faso were analysed.  Genomic DNA was 
extracted from filter papers using the Chelex-100 method and different 
Plasmodium species were analysed by microscopy and species-specific 
nested-PCR.  
 
The mutation in pfcrt which was associated with CQ and AQ 
resistance was analysed using pyrosequencing, and in vitro susceptibility of 
clonal parasites to CQ, AQ and DQ was determined. Three different 
phenotypes of P. falciparum (S9, S47, S173) based on the IC50 values were 
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cultured and the clonal lines were obtained. All clones from S9 and S47 
harboured pfcrt CVIET haplotypes while all clones from S173 were CVMNK 
haplotype. The clones from S9 showed higher IC50 values on average to CQ 
and AQ compared to S47 clonal parasites. Some clones were sensitive to DQ 
for S9 and all were sensitive in clonal lines for sample 47. Clonal parasites 
from S173 has lower IC50 values towards CQ. Responses to CQ, AQ and DQ 
varied between the clones. Clear cross-resistance were observed in clonal 
lines S9, eg. 9C9, 9C7, 9H8 and in clone S47E8. There was a moderate 
correlation between AQ and DQ and a weaker correlation between AQ and 
CQ.  Cross resistance exists but not high in the clonal lines.   
 
After a consistence result of IC50, 9C6, 47C7 and 173D3 were selected 
for the drug accumulation study. Accumulation of CQ and AQ does not 
always correlate with IC50. It appeared that clones accumulating high levels 
of CQ and AQ were susceptible to CQ and AQ respectively, while clones 
accumulating lower CQ and AQ were resistant. High CQ and AQ IC50 values 
were associated with lower amounts of drug uptake and the two response 
parameters reciprocally correlated to each other. Long-term and continuous 
culture can cause loss of the resistance phenotype.  From the observations 
and findings of this study, we concluded that Pfcrt plays a major role in the 
resistance to CQ and AQ and we suggest that one or more genes or SNPs 
may be involved in AQ drug resistance.  
 
There were no resistant clones isolated from the in-vitro selection 
strategy after challenge with 60 nM DQ but suggested dormant parasites to 
DQ developed after the exposure. After investigation using quantitative 
recrudescence assays, the parasites were not dormant but were in fact 
dead.  Several strategies and processes could be improved for future studies 
to select for AQ resistant parasites. 
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Zusammenfassung 
Zusammenfassend haben wir eine abnehmende Tendenz der Malaria 
Transmission in Nouna Burkina Faso während der Regenzeit von 2009-2011 
festgestellt. Einzel- und Mischinfektionen durch P. falciparum und P. malariae waren 
im Vergleich zu den Basisdaten (Regenzeit 2000) signifikant reduziert und ein 
verringertes Vorkommen von P. malariae stand im Zusammenhang mit einer 
geringeren Transmissionsintensität. Die mikroskopische Untersuchung hat ein 
geringeres Detektionslimit und führt zu einer Unterschätzung der tatsächlichen 
Parasitenbelastung. Daher wäre eine molekular-diagnostische Diagnose wie PCR eine 
sensitivere Methode um das Vorkommen von Malaria zu bestimmen. 
Amodiaquin (AQ) ist ein Antimalariawirkstoff, welcher chemisch und 
funktional mit Chloroquin (CQ) verwandt ist. Aktuell ist es in einigen afrikanischen und 
südamerikanischen Ländern in Kombination mit Artesunat (AS) das Mittel der Wahl 
um unkomplizierte P. falciparum Malaria zu behandeln. In Burkina Faso wurden 
Chloroquin-resistente Parasiten sowie eine Kreuzresistenz zwischen CQ und AQ bzw. 
dessen aktivem Metabolit Desethyl-Amodiaquin (DQ) beobachtet. pfcrt und pfmdr1 
sind genetisch mit dem Resistenzmenchanismus in Verbindung stehende Gene, wobei 
der zugrundeliegende Mechanismus für Kreuzresistenzen weiterhin diskutiert wird.  
Ein weiteres Ziel der Studie war die Suszeptibilität klonaler Parasiten von P. 
falciparum im Vergleich zu Referenz Laborstämmen (DD2 and HB3) zu bestimmen. 
Blutproben von 402 Patienten des Dorfes Bourasso, Nouna, Burkina Faso wurden 
analysiert. Genomische DNA wurde mit der Chelex-100 Methode aus Filterpapieren 
extrahiert und verschiedene Plasmodium Spezies wurden mikroskopisch sowie mittels 
Spezies spezifischer nested-PCR analysiert. Die mit der CQ und AQ assoziierte 
Mutation in pfcrt wurde mittels Pyrosequenzierung analysiert und die in vitro 
Suszeptibilität klonaler Parasiten gegen CQ, AQ und DQ bestimmt. Auf Grundlage der 
IC50 Werte wurden drei unterschiedliche Phänotypen von P. falciparum (S9, S47, S173) 
kultiviert und die klonalen Linien erhalten. Alle Klone von S9 und S47 enthielten den 
pfcrt CVIET Haplotyp, während alle Klone von S173 den Haplotyp CVMNK aufwiesen. 
Die Klone von S9 wiesen im Vergleich zu klonalen Parasiten von S47 durchschnittlich 
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höhere IC50 Werte mit CQ und AQ auf. Während nur einige Klone von S9 sensitiv gegen 
DQ waren, waren alle klonalen Linien von S47 sensitiv. Klonale Parasiten von S173 
hatten geringere IC50 Werte auf CQ. Die Reaktionen auf CQ, AQ und DQ variierten 
zwischen den Klonen. Eine klare Kreuzresistenz wurde in den klonalen Linien von S9 
z.B. 9C9, 9C7, 9C8 und im Klon S47E8 festgestellt. Es zeigte sich eine moderate 
Korrelation zwischen AQ und DQ sowie eine schwächere Korrelation zwischen AQ und 
DQ. Eine Kreuzresistenz existiert, war in den Klonalen Linien jedoch nicht stark 
vertreten. 
Nach einem konsistenten Resultat des IC50 wurden 9C6, 47C7 und 173D3 für 
Wirkstoffakkumulationsstudien ausgewählt. Die Akkumulation von CQ und AQ 
korreliert nicht immer mit dem IC50. Es wurde dargestellt, dass Klone welche große 
Mengen an CQ und AQ akkumulierten entsprechend empfindlich gegen CQ und AQ 
waren, während Klone welche geringere Mengen an CQ und AQ akkumulierten 
resistent waren. Hohe CQ und AQ IC50 Werte standen in Verbindung mit einer 
geringeren Menge an Wirkstoff und die zwei Antwortparameter korrelierten 
zueinander reziprok. Langzeit und Dauerkultur kann den Verlust des resistenten 
Phänotyps verursache. Wir schlossen aus den Beobachtungen und Ergebnissen dieser 
Studie, dass Pfcrt eine wesentliche Rolle bei der Resistenz gegen CQ und AQ spielt und 
schlagen vor, dass ein oder mehrere Gene oder SNPs in der Resistenz gegen AQ 
involviert sein könnten. 
Die in vitro Selektionsstrategie resultierte nach der Exposition mit 60nM DQ 
nicht in resistenten Klonen sondern wies auf die Entwicklung dormanter Parasiten 
nach der Exposition mit DQ hin. Quantitative Rekrudeszenz Assays ergaben, dass die 
Parasiten nicht dormant sondern tatsächlich tot waren. Einige Strategien und Prozesse 
konnten für zukünftige AQ Resistenz Selektionsstudien verbessert werden. 
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1.0 Introduction  
  
Malaria has been an important disease affecting public health, for 
many years in both tropical and subtropical countries and is a major cause 
of death. Approximately, 3.3 billion people in 97 countries are at risk, 
leading to an approximately 200 million cases and about 600,000 deaths 
(WHO, 2015). Malaria is a vector-borne disease causing an infection due to a 
protozoan parasite, Plasmodium. From 120 Plasmodium species that infect 
land vertebrates, only six Plasmodium species are a major threat to human 
health (Boddey and Cowman, 2013). Of them, Plasmodium falciparum is one 
of the most important in terms of death. Plasmodium vivax is a major cause 
of illness in many regions and death due to this parasite has been 
underestimated (Naing et al., 2014). Nevertheless, P. vivax causes half of the 
malaria cases and is responsible for between 3.5% and 16% of the total 
deaths in sub-Saharan (WHO, 2015).  
 
Furthermore, P. vivax is able to cause multiple relapses since it can 
stay dormant in infected liver cells as hypnozoites (Imwong et al., 2007). P. 
ovale curtisi, P. ovale wallikeri, and P. malariae are less common in causing 
significant disease burden. P. ovale also can cause relapses but there is no 
evidence that these parasites could generate hypnozoites (Richter et al., 
2010). Nonetheless, Cogswell et al., (1991) reported hypnozoites in monkeys 
infected with P. simiovale, an analog of P. ovale. Another plasmodia species, 
Plasmodium knowlesi, a simian malaria parasite is an important zoonosis 
affecting people in Malaysia and other countries in South East Asia (Ahmed 
and Cox-Singh, 2015). 
        
1.1 Malaria: Origin and history 
   
The word malaria originates from mid 18th century Italian, mala aria 
meaning ‘bad air’, because malarial fevers were associated with swampy 
marshes in Italy where the disease was observed (Haldar et al., 2007).  
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Periodic fevers similar to malaria has been reported more than 4000 years 
ago. A Chinese medical document, Nei Ching from 2700 BC, mentioned the 
symptoms of fever were associated with splenomegaly which suggested the 
infection was due to Plasmodium parasites, the causative agent of malaria. 
Similarly, in the Susruta, a Sanskrit medical article, the symptoms of malarial 
fever were described and attributed to the bites of certain insects. During 
the Roman Empire and in Greece, malaria-like fever epidemics were 
reported to kill large proportions of the population. The first person who 
connected stagnant water bodies with malaria infection in the local 
population was Hippocrates, whose findings were later supported by the 
Romans (CDC, 2009).  
  
A French army surgeon, Charles Louis Alphonse Laveran first noticed 
malaria parasites in 1880 in the blood of a patient who was suffering from 
malaria. For this discovery, he was awarded the Nobel Prize in 1907. Later in 
1886, an Italian neurophysiologist, Camillo Golgi, discovered two different 
forms of the disease, with tertian and quartan periodicities. In 1890, 
Giovanni Batista Grassi and Raimondo Filetti first introduced the names P. 
vivax and P. malariae for two of the malaria parasites that affect humans. It 
was believed that there was only one parasite species according to Laveran, 
Oscillaria malariae but an American researcher, William H. Welch revised 
the subject again. In 1897, he named the third malaria parasite P. 
falciparum, which is widely prevalent today (Carter and Mendis, 2002) and 
in the same year Ronald Ross, a British officer in the Indian Medical Service, 
was the first to demonstrate that malaria parasites could be transmitted 
from infected patients to mosquitoes.  Later in 1922, John William Watson 
Stephens described the fourth human malaria parasite P. ovale while the 
fifth malaria parasite, P. knowlesi, was first described by Robert Knowles and 
Biraj Mohan Das Gupta in 1931 in a long-tailed macaque (CDC, 2009).  
 
The ancestors of malaria parasites possibly led a parasitic existence 
since there were other potential hosts to parasitize. Molecular genetic 
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evidence strongly suggests that this ancestor was a chloroplast-containing, 
free-living protozoan, which became adapted to living in the gut of a group 
of aquatic invertebrates (Wilson et al., 1997). The single cell organism most 
likely had an obligate sexual reproduction and certainly, in the present time, 
all Apicomplexan including malaria parasites have retained obligatory sexual 
reproduction in their life cycles (Kudo, 1971). The ancestors of malaria 
parasites were perhaps adapted to aquatic insect larvae including early 
Dipterans, the taxonomic order in which mosquitoes and blood-sucking flies 
also belong. When the first insects appeared around 150 million to 200 
million years ago, certain lines of the ancestral malaria parasites attained 
two-host life cycles that were adapted to blood-feeding habits of the insect 
host.  
 
After the presence of the early Dipterans, many different lines of 
malaria and malaria-like parasites evolved and radiated. Speculation 
regarding the evolution of Plasmodium species was elucidated with modern 
molecular techniques on genetic analysis (Fig 1.0). Based on the molecular 
data (Escalante et al., 1998) and biological classification (Garnham, 1996) P. 
falciparum is closely related to P. reichenowi, a malaria parasite infecting 
chimpanzees and surprisingly both are closely related to P. gallinaceum, a 
bird malaria parasite compared to other mammals. The other three human 
malaria parasites, P. malariae, P. ovale and P. vivax fall within a single clade 
that includes all mammalian malaria parasites (Escalante et al., 1998). 
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Figure 1.0  Phylogeny of malaria parasites of humans and of some other related 
malaria parasite species.     
 
 
1.2 Epidemiology 
 
It was estimated 216 million cases of malaria occurred worldwide in 
2016 compared to 2015 with 211 million cases and in 2010 with 237 million 
cases (WHO, 2017).  Majority of the cases in 2016 were in WHO Africa 
region (90%), WHO South-East Asia region (7%) and WHO Eastern 
Mediterranean region (2%). 15 countries, all in sub-Saharan Africa except 
India carried 80% of the global malaria burden.  
 
There was a decreased from 76 to 63 cases per 1000 population at 
risk (estimated 18% globally) in the incidence rate of malaria between 2010 
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and 2016. P. falciparum is still the most prevalent parasite in sub-Saharan 
Africa while P. vivax is the predominant parasite in the WHO Region of the 
Americas representing 64% malaria cases, > 30% in WHO South East Asia 
and 40% in the Eastern Mediterranean regions (WHO, 2017). 
 
In 2016, there were an estimated 445000 deaths from malaria 
globally compared to 446 000 estimated death in 2015. All regions recorded 
a decreased in mortality in 2016 when compared to 2010 except the WHO 
Eastern Mediterranean Region. A significant declined occurred in WHO 
regions of South East Asia (44%), Africa (37%) and the Americas (27%). 
 
Countries with zero indigenous cases over at least the past three 
consecutive years are qualified to apply malaria free certificate status from 
WHO. In 2016, all countries in the WHO European Region were reported 
free from malaria cases. Two countries, India and Kyrgyzstan were certified 
malaria free in 2016 (Fig 1.1). In 2016, WHO has identified 21 countries 
potentially can eliminate malaria by the year 2020 which known as E-2020 
countries to support their eradication acceleration targets. 
 
 
Figure 1.1 Countries and territories with indigenous cases in 2000 and their 
status by 2016 (WHO,2017) 
 
  Introduction 
6 
 
1.3 Biology of Plasmodium  
  
The protozoan parasite Plasmodium (Phylum: Apicomplexa, Class: 
Sporozoa, Order: Coccidia, Suborder: Haemosporidiae, Family: 
Plasmodiidae) causes an infection that is transmitted by an infectious bite of 
a female Anopheles mosquito. The life cycle of the malaria parasite is very 
complex and involves two hosts, a vertebrate and an invertebrate host. The 
infection starts when an infected Anopheles mosquito inoculates 
approximately 100 threadlike sporozoites into the skin of the mammalian 
host. These sporozoites are actively motile and carried by the bloodstream 
from the skin to various tissues and organs of the body.  
 
The sporozoites are transported to the liver (Amino et al, 2006) 
where they traverse the sinusoids via Kupffer or endothelial cells and enter 
a hepatocyte.  Active invasion is preceded by cellular traversal until a 
suitable hepatocyte is found. There, they form a parasitophorous vacuole 
membrane (PVM) and undergo asexual replication so called exo-erythrocytic 
schizogony until tens of thousands of daughter merozoites within 6 to 10 
days, depending on the Plasmodium species. PVM surrounds the invading 
sporozoites and builds up a physical barrier between the parasite and the 
host (Lingelbach and Joiner, 1998). Later merozoites are released from the 
liver cell into the lumen of the liver sinusoids in packets of merosomes, 
parasite-filled vesicles (Sturm et al., 2009) into the vasculature. Once in the 
vasculature, the merosomes burst releasing the merozoites in the 
bloodstream (Prudencio et al., 2006) and begin a chronic cycle of asexual 
schizogony so-called intraerythrocythic schizogony.  P. vivax and P. ovale 
furthermore develop hypnozoites in the liver, the latent forms which can 
stay dormant for many years until they are reactivate and cause a relapse in 
malaria disease (Cogswell, 1992). 
 
In the bloodstream, merozoites bind and invade red blood cells (RBC) 
in a multistep processes including pre-invasion, active invasion and 
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echinocytosis (Weiss et al., 2015). The binding is mediated by host receptors 
and parasite surface protein especially the merozoite surface protein family 
such as merozoite surface protein 1 (MSP1). It is a major 
glycophosphatidylinositol (GPI)-associated protein on the merozoite surface 
and act as a platform on the merozoite surface (Holder, 1994). Merozoites 
can bind the RBC at any point on the surface but when they are attached, 
they reorient with the apical end pointing to the RBC. A tight junction is then 
formed, producing an irreversible attachment. Rhoptries secrete RON2 at 
tight junction and insert into the erythrocyte membrane, links the parasite 
with the host cell membrane through its binding to AMA1 (Richard et al., 
2010) 
 
In P.falciparum, the intraerythrocytic cycle lasts 48 hours and causes 
the clinical symptoms associated to malaria. Later, merozoite develops from 
ring to metabolically very active trophozoite and finally to schizont. When 
RBC ruptures, approximately, 10-30 merozoites are produced depending on 
parasite strains (Bannister et al., 2000) from each schizont then invade new 
erythrocytes, starting a new cycle of schizogony. 
 
Some merozoites are reprogrammed to undergo gametocytogenesis. 
Gametocyte development is divided into five stages. However only stage I 
and stage V gametocytes are found in the bloodstream and other stages 
sequester in bone marrow. Within a 15-day period, once mature the 
gametocytes re-enter the peripheral circulation for ingestion by a mosquito 
where they emerge as extracellular male and female gametes in the midgut. 
Mating occurs by fusion of micro- and macrogametes to form a zygote that 
transforms over 24 hrs into an ookinete that migrates through the mosquito 
midgut epithelium and encysts to become an oocyst where asexual 
sporogenic replication occurs. Motile sporozoites are released into the 
hemocoel by oocyst rupture and travel to the salivary glands from where 
they can be injected into the next human host (Cowman, 2016).  
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Figure 1.2 Life cycle of a Plasmodium in human and a mosquito (Cowman  et 
al., 2016) 
 
1.4 Clinical Manifestation 
 
The clinical manifestations of malaria depend on several factors such 
as geography, epidemiology, immunity and age.  In highly endemic areas, 
groups at highest risk include small children from 6 to 36 months who are 
able to develop severe illness, while pregnant women are at risk of anemia 
and delivering low birthweight new-borns. In areas where malaria is 
transmitted throughout the year, older children and adults develop partial 
immunity after repeated infections and are at relatively low risk for severe 
disease. 
  
 Unlike viral or bacterial infections, the  typical symptoms of malaria 
are characterized by periodic fibrile episodes accompanied by chills, rigors 
and sweating. This is due to the release of parasite toxins into the 
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bloodstream during the erythrocytic cycles of merozoite egress and 
reinvasion of erythrocytes (Renia et al., 2016).  Other common symptoms 
observed are headache, muscle pain, and nausea. If left untreated, 
uncomplicated malaria can progress to severe malaria within a few days and  
the outcome is 10-40% of all severe malaria cases are fatal (Schlitzer, 2007).  
When the disease progresses, it happens in several stages which last 6-10 
hours. It started with a cold stage where patient feels cold and then 
followed by hot stage where fever develops along with headache and 
nausea. Patient also showed symptoms such as sweating and weakness. The 
intervals at which symptoms occur is correlated to TNF-α release from 
machrophages as a response to rupturing erythrocytes (Kwiatkowski et al., 
1989). In the case of P. falciparum, parasite egress from erythrocytes is 
regularly unsynchronized which leads to persistent fever (Rasti et al., 2004). 
 
Severe malaria is defined by P. falciparum infection, which causes 
dysfunction of organs, metabolic disequilibrium and the sequestration of 
parasites in the blood capillaries in the brain. The clinical spectrum of 
malaria in African children includes severe anaemia, coma and respiratory 
distress (Marsh et al., 1995). Anaemia is the result of erythrocyte 
destruction and suppression of erythropoiesis (Clark and Chaudhri, 1988) 
while coma happens in celebral malaria when the infected erythrocytes 
adhere to the brain microvasculature. Such cytoadherence is the product of 
PfEMP1 family proteins (Kirchgatter et al., 2005).  All these pathologies can 
eventually lead to death (Milner et al., 2014) 
  
Travelers visiting countries with high malaria cases generally and 
have no previous exposure to malaria parasites or have lost their immunity 
if they leave the endemic area, are at very high risk of severe disease if 
infected with P. falciparum. For this reason, it is important to consider 
malaria in all febrile patients with a history of travel to malaria-infected 
areas. 
  
  Introduction 
10 
 
1.5 Antimalarial drugs 4-Aminoquinolines 
  
It has been known the 4-Aminoquinolines, chloroquine (CQ) and 
amodiaquine (AQ), are the most important drugs to control and eliminate 
the infectious disease, malaria. Previously CQ was used as the first line 
treatment before it was replaced by sulphadoxine-pyremethamine (SP) 
while AQ is used as the second line treatment to treat uncomplicated 
malaria. However, SP was replaced by artemisinin combination therapy 
(ACT) in 2006 (Mohammed et al., 2013). The use of these two drugs are 
based on the excellent clinical efficacy, limited host toxicity, simple 
application and cost-effective synthesis. Generally, CQ therapy is 
inexpensive and practical to be used in the developing countries but has 
been reduced mainly as a result of the development and spread of parasite 
resistance. 
 
Quinine (QN) is one of the oldest antimalarial drugs belonging to the 
cinchona alkaloid family. In the late 1600s, QN was first extracted from the 
bark of a cinchona tree. The Dutch and the British colonialists established 
plantations in countries, which they colonized in South-East Asia, in after the 
therapeutic potential of this tree was discovered. The Chinchona species is 
native to the Andean region of South America, but during World War II, the 
plantations were lost to the Japanese who initiated more research for 
synthetic analogues based on the QN template, such as the 4-
aminoquinoline chloroquine and AQ. 
 
Appendix 4.0 listed the antimalarial drugs used as monotherapy and 
summarized the quinolone derivates commonly used as antimalarial drugs 
along with their mechanism of action and validated molecular markers to 
determine their drug susceptibility or resistance.  
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1.5.1  Chloroquine 
 
Chloroquine (CQ) is a 4-aminoquinoline (Foley et al., 1998). CQ is 
absorbed when consumed orally and available intramuscularly (IM) and 
intravenously (IV). The drug acts against the Plasmodium parasite during the 
asexual intra-erythrocytic phase of its lifecycle (Lehane et al., 2011). It is 
metabolized in the liver and mainly to monodesythylchloroquine (WHO, 
2006). This drug is an amphiphilic weak base and accumulates in the 
parasite food vacuole because of the pH gradient.  
 
Parasite metabolism uses its main food source, haemoglobin in the 
food vacuole. Heme (ferriprotoporphyrin IX),  which is released as a 
byproduct of hemoglobin digestion, is oxidized to hematin and sequestered 
into hemozoin or malarial pigment by an autocatalytic mechanism (Dorn et 
al., 1995). CQ inhibits the polymerization process in vitro and is anticipated 
the same in vivo, causing a formation of free hematin or 
hematin/chloroquine complex that would finally kill the parasite (Sullivan et 
al., 1996). On the other hand, it has been suggested that weakly basic CQ 
accumulates to high levels in the acid food vacuole by a proton-trapping 
mechanism (Yayon et al., 1985). Therefore, CQ could lead to parasites death 
by direct inhibition of vacuolar enzymes such as phospholipase (Ginsburg 
and Geary, 1987) or proteinase (Vander Jagt et al., 1987).  
 
In 1934, CQ was first synthesized and became widely used by late 
1940s (Loeb et al., 1946). It has been a successful antimalarial drug due to 
its effectiveness, safety, low cost and antipyretic properties. Resistance to 
CQ emerged in the late 1950s, first in South-East Asia (Thai-Cambodian 
border) and in South America (Colombia and Venezuela) (Harinasuta etal., 
1965, Moore et al., 1961). The spread was rapid and was also discovered in 
East Africa (Kenya and Tanzania) in the late 1970s (Kihamia et al., 1982, Fogh 
et al., 1979.) In the early 1980s, it was first reported in West Africa 
(Sansonetti et al., 1985, Hellen et al., 1987). Until early 2000s, although 
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there was relatively high prevalence of CQ resistance in Africa for more than 
two decades, CQ was still used and remained as the first-line treatment of 
uncomplicated malaria Plasmodium falciparum.  
 
Regrettably, a significant increase in morbidity and mortality in 
children under five years was due to CQ resistance from 1980s to 1990s 
(Korenromp et al., 2003, Trape et al., 2001). Malawi was the first African 
country to change its national drug policies from CQ to SP in 1993 followed 
by Kenya in 1998 (Oochong et al., 2009) and Tanzania in 2001 (Taverne et 
al., 2001). Soon, all malaria-endemic countries in Africa stopped the use of 
CQ against P. falciparum. The change of policy to ACT as a first-line 
treatment for uncomplicated P. falciparum malaria occurred in all endemic 
countries between 2000 and 2009  (Gharbi et al., 2013). 
 
 
 
                                                      
 
 
 
 
 
 Currently, molecular study has shown multiple CQR mutations and a 
large scale CQR selective sweep from Southeast Asia to Africa as well as 
other sweeps across the Amazon in South America and in PNG (Wootton et 
al., 2002). Wellems et al., (1990) first defined a ~400 kb DNA segment on 
chromosome 7 that was associated to CQR in an analysis of 16 progeny of a 
genetic cross of a CQ drug sensitive, HB3 and drug resistant strain, Dd2.  
Then the CQR locus was narrowed to a ~36 kb region using high density 
microsatellite markers (Su et al, 1997) which resulted in the identification of 
Figure 1.3  Chloroquine 
  Introduction 
13 
 
multiple mutations in the parasite pfcrt gene that is associated with CQ 
resistance (Djimde et al., 2001) in parasites from Asia, Africa and South 
America (Fidock et al., 2000). The discovery of pfcrt , a ~3.1 kb gene with 13 
exons encoding a transmembrane protein PfCRT (424 amino acid, 48.6 kDa); 
and multiple nucleotide substitutions in the gene were found to be linked 
with CQR. PfCRT is predicted to have ten transmembrane domains and is 
sited on the membrane of the parasite DV (Cooper et al., 2002).  
 
 
1.5.2 Amodiaquine 
 
Initially, Amodiaquine (AQ) was developed during World War II to 
develop substitutes for quinine by the US Army under a sponsored program 
(Steck, 1971). It was extensively used both prophylactically and 
therapeutically. AQ is a central drug in the new global strategy of 
combination therapies for the control of malaria (Meschnik, 2005). AQ, a 4-
aminoquinoline that differs from chloroquine in having a 4- hydroxyanilino 
functional side chain. The medical product is known as amodiaquine 
hydrochloride and was first established to be effective against non-human 
malaria in 1946.  
 
AQ is mainly metabolized by hepatocytes into its major active 
metabolite desethylamodiaquine (DQ), by the polymorphic P450 isoform 
CYP2C8 (Gil, 2008). The mechanism of action is thought to be similar to CQ, 
but it is still unclear. AQ is an alternative to CQ and is cheap and easily 
obtain in several countries, some with local production facilities. It is edible 
and easier to give to children compared to CQ. Another advantage of AQ is 
the long half-life of its principal active metabolite, DQ (9–18 days) (Pussard 
et al., 1987). In 1990, WHO suggested combination therapy of AQ 
particularly with artemisinin derivatives to treat uncomplicated malaria. 
Artemisinins are short-acting antimalarial drugs and their combination 
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therapy with long-acting drugs delay the development of P. falciparum drug 
resistance.  
 
The clinical use of AQ has been severely restricted because of 
associations with hepatotoxicity and agranulocytosis. Due to this toxicity, 
WHO withdrew recommendation for the drug as a monotherapy in the early 
1990s. Later, it was only reintroduced for therapeutic use. To date, there is 
no evidence for serious toxicity associated with AQ therapy (Olliaro and 
Mussano, 2003). 
 
The AQ side chain contains a 4-aminophenol group; a structural alert 
for toxicity, because of metabolic oxidation to a quinoneimine. Although 
cross-resistance of CQ and AQ has been documented for 20 years, AQ 
remains an important drug due to its effectiveness against many CQ-
resistant strains (Daily, 2009). Therefore, many drug design projects have 
since focused on reducing this toxicity. 
  
 Not much is known about the mechanism or epidemiology of 
amodiaquine resistance. In vitro studies showed that resistance to CQ and 
AQ are correlated; however, CQR strains appear to have lower levels of 
resistance to AQ (Ringwald et al., 1999). There is also evidence that AQ is 
effective against CQR malaria in vivo (Graupner et al., 2005). However, AQ 
resistance occurs in areas where it has been used frequently (Rwagacondo 
et al., 2004).  More effort on this issue is clearly required. 
 
                                                                      
 
 
       Figure 1.4  Amodiaquine 
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Figure 1.5  Desethyl-Amodiaquine 
 
 
1.6 Genetic Markers  
 
1.6.1. Plasmodium falciparum chloroquine resistance transporter (PfCRT) 
 
The pfcrt gene has 13 exons and encodes a 424 amino acid 
transmembrane protein with a molecular mass of 48.6 kDa and localized to 
chromosome 7 (Fidock, 2000). The PfCRT protein belongs to the 
drug/metabolite transporter superfamily and chloroquine resistance 
transporter-like transporter family which contains 10 putative 
transmembrane domains spanning the digestive vacuole membrane of the 
parasite (Martin, 2004). Sanchez et al., (2005) reported several studies 
comparing the wild and mutant pfcrt allele expression showed less CQ 
accumulation when pfcrt was mutated as compared to wild-type pfcrt.  The 
active transport mechanism of mutant PfCRT in the resistant parasite caused 
differences in the CQ accumulation (Sanchez, 2007).  Juge et al., (2015) 
showed recombinant CQ-sensitive protein (PfCRT 3D7) and CQ-resistant 
protein (PfCRT Dd2, PfCRT 7G8, PfCRT K76T [with K76T mutation in the 3D7 
gene background]) were purified and both were found to transport CQ 
molecule. Furthermore, higher CQ transport activity was observed with CQ-
resistant protein while higher accumulation of CQ was measured with CQ-
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sensitive protein by a proteoliposome study. Therefore, the CQ-resistant 
variants displayed decreased affinity toward CQ with increased transport 
activity, which lead to less accumulation of CQ in the digestive vacuole, 
hence conferring CQ resistance (Juge et al., 2015). 
 
Mutations in the pfcrt  gene plays a important role in determining CQ 
resistance and its phenotype. The K76T mutation is a main determinant of 
CQ resistance and susceptibility (Fidock et al., 2000). The K76T mutation is 
found in the first transmembrane domain of PfCRT protein, consists of a 
positively charged lysine residue which is substituted by a neutrally charged 
threonine residue at 76th position, and permits the efflux of diprotonated 
CQ out of the digestive vacuole by active transport. Additional common 
mutations in other regions (C72S, M74I, N75E, A220S, Q271E, N326S, I356T, 
and R371I) also confer resistance, but only in association with K76T 
mutation (Martin et al., 2004). 
 
Variation in PfCRT protein effects antimalarial drug susceptibility and 
resistance to other drugs such as quinine, amodiaquine (AQ), piperaquine 
and lumefantrine (Sisowath et al., 2009). CQ and AQ shows cross-resistance 
with AQ and quinine mainly mediated by 76T. The PfCRT mutations at 72-76 
codons confer higher resistance to CQ and medium level AQ resistance in 
Southeast Asia and Africa while it is associated with greater AQ resistance in 
South America (Reed et al., 2000). Consequently, K76T mutation in PfCRT 
protein is an effective molecular marker for the antimalarial drug, subjected 
to the earlier use in the region. 
 
1.6.2 Plasmodium falciparum multidrug resistance (PfMDR) 
 
Another gene which is linked to CQR is the  P. falciparum multidrug 
resistance protein 1 gene (pfmdr1). It is located on chromosome 5 consist of 
one exon encoding for P-glycoprotein homolog 1 (pfPgh1) protein of 1419 
amino acids and 162.25 kDa molecular mass (Duraisingh et al., 2005). 
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PfMDR1 is a transmembrane protein with two domains, each consisting of 6 
helical transmembrane domains and a nucleotide binding fold region that 
acts as a site for ATP binding. Similar to PfCRT, it is also exist in the digestive 
vacuole of the parasite and belongs to the ATP-binding cassette (ABC) 
superfamily. Polymorphism, amplification and variation in mRNA expression 
levels of the pfmdr1 gene have been involved in resistance to numerous 
antimalarials and development of multi-drug resistance parasites  
(Duraisingh et al., 2005) 
 
Drug susceptibility to CQ, quinine (QN), mefloquine (MQ), 
halofantrine, lumefantrine, and artemisinin involves mutation in the 
pfmdr1 gene at the following position (N86Y, Y184F, S1034C, N1042D, and 
D1246Y). (Sidhu et al., 2006). PfMDR1 mutations at N86Y and N1042D 
positions are associated with AQ resistance. K76T and A220S mutation in 
the pfcrt gene and N86Y mutation in the pfmdr1 gene are associated with 
high resistance to CQ in field isolates. In addition, copy number variation 
of the pfmdr1 gene has been related to greater level of resistance to QN, 
MQ, halofantrine, lumefantrine and artemisinin (Sidhu et al., 2006). 
    
1.7  Plasmodium falciparum drug-resistant selection  
 
The in-vitro selection of P. falciparum drug resistant parasites was 
started in 1978 by Nguyen-Dinh and Trager (Nguyen, 1978) using the petri 
dish method. A parasite line from a Gambian (West Africa) strain (FCR3), 
which was resistant to 100 ng/ml CQ was generated by increasing 
chloroquine concentrations, starting at 10ng/ml. After 2 months (15 cycles), 
a parasite line that could grow in 100 ng/ml chloroquine was chosen. The 
resistant phenotype was stable since it could grow in drug–free medium 
without losing the selected features. This work has been a breakthrough, as 
it opened up the opportunities that a resistant strain could be chosen 
against an antimalarial in vitro. 
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The aim of inducing in vitro resistance was to generate parasite lines 
that can be used to investigate resistance mechanism. Many in vitro 
selection studies have been conducted such as parasite lines that were 
resistant against MQ in 1980s (Brockelman et al, 1981) and another 
selection study by Barnes et al., (1992) on chloroquine resistant parasites 
revealed the inverse relationship between pfmdr1 copy numbers 
(mefloquine resistance) and chloroquine susceptibility. This later study 
initiated further investigations into pfmdr1 polymorphism in relation to 
chloroquine susceptibility (Barnes et al. 1992). SNPs in this gene have been 
associated to chloroquine resistance and it has been recognized that pfmdr1 
plays an ancillary role in chloroquine resistance, while the primary gene is 
still pfcrt  (Valderramos et al. 2006, Sanchez et al. 2007, Ekland et al. 2007). 
 
 
1.8 Aims of study 
 
The objectives of this study are as below: 
 To study the prevalence of Plasmodium species by microscopy and 
PCR methods in order to perceive the variation between the dry 
and wet season over a period of time. 
 To isolate and characterize the amodiaquine-resistant Plasmodium 
falciparum strains from Bourasso, Burkina Faso. 
 To assess the in vitro susceptibility patterns of selected 
Plasmodium falciparum clonal parasites to a panel of 
Aminoquinoline drugs by using SYBR Green-fluorescent based 
method. 
 To analyse the association between genotypic drug resistance 
with the phenotypic information by in vitro susceptibility testing 
(IC50).
 
  Material and Methods 
19 
 
2.0 Materials and Methods  
The underlying mechanism of AQ resistance is still not clearly understood and 
isolation of AQ resistant strains from field isolates might resolve as yet unanswered 
questions. AQ resistance may be less common than CQ resistance and cross-resistance 
between these drugs has been observed, suggested that the drugs share a common 
resistance mechanism.  In this section, several methods are described detailing how 
the main objectives of this study were achieved.  
Briefly, there were two strategies applied in isolating the AQ resistant 
parasites. In the first strategy, a group consisting of samples from 402 donors was 
chosen from October 2009 during the rainy season, confirmed positive for AQ and DQ 
in the serum, by the Pharmacology/Epidemiology Department. Samples identified as 
positive by microscopy were cultured and field isolates were then characterized by 
genotyping the pfcrt gene and performing phenotypic analysis by techniques such as 
in-vitro susceptibility (IC50) and drug transport assays. 
Secondly, a subsample that were positive by microscopy (approximately 200 
samples) was chosen and challenged with the drug (60 nM DQ) as soon as the 
parasites appeared for two cycles. The sections below discuss each of the methods as 
used to accomplish the aims of this study.   
2.1 Study Site 
Burkina Faso is a landlocked country in Africa surrounded by six other nations 
(Mali, Niger, Benin, Tongo, Ghana and Ivory Coast) with the capital city Ouagadougou 
situated in the Province of Kadiogo in the north-west of Burkina Faso (Okrah et al., 
2002). This study was conducted in a rural village of Bourasso, some 23 km from the 
research center of CRSN in Nouna. Nouna is the capital of the Province of Kossi and 
the area around Nouna town is typical of the West African savanna zone (Stich et al., 
2006).  
The city includes about 20,000 inhabitants in a nation with a total population 
of about 18.7 million. Nouna area is a dry orchard savannah, populated with farmers 
of many different ethnic groups. The area has a sub-Saharan climate, with a mean 
annual rainfall of 796 mm (range 483-1083 mm) over the past five decades. Malaria is 
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known to be holoendemic in this region, with prevalence highest during the rainy 
season; nevertheless, data on the occurrence of infection with different plasmodial 
species and morbidity to malaria are scarce, especially in adults. Most cases of malaria 
are recorded during or shortly after the rainy season, which lasts from June to of 
October (Muller et al., 2001). 
 
 
                  Figure 2.0 : Study site at Bourasso, Nouna, Burkina Faso 
 
2.2 Study design and sampling 
The first part of this study was designed to characterise the epidemiology of 
malaria in Nouna, Burkina Faso from October 2009 until April 2012, in addition to 
molecular markers associated with drug resistance between the wet and dry seasons. 
C. Geiger (2013) from AG Lanzer laboratory has conducted the first part of the study. 
The second part of this study was to understand the AQ resistance which has been 
reported in Burkina Faso since the implementation of AQ as a combination therapy 
with artesunate. Some parts of the epidemiological data and samples were shared and 
used to understand the resistance mechanism of this antimalarial drug. 
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A total of six sampling procedures were performed every six months from 
October 2009 to April 2012, of which three samples were conducted at the end of the 
rainy season in October and three more samples at the end of the hot dry season in 
April. The villagers who participated were invited based on randomized list generation 
to eliminate selection bias. An approval from the village council was obtained after 
extensive reconnaissance and written informed consent was obtained from the 
participants and/or parents representing their young children. Ethical approval was 
granted by both the ethics committee of the University Hospital Heidelberg, and by 
the Ethics Committee of the Centre de Recherche de Santé Nouna (CRSN). 
2.3 Representatives 
An article was published by Stich et al., (2006) to assess malaria endemicity in 
Western Burkina Faso within the entire population (n=1,561), including adults and 
children in year 2000. The figures and results were used as a reference study for this 
recent project. During the rainy season, prevalence of parasites was 80% and there 
was no published data for the dry season but was estimated by the team member to 
be approximately 15 %. A total of 1767 individuals participated in the study between 
October 2009 and April 2012. 
 
 
Year 
Season / No of participants 
Rainy (October) Dry (April) 
2009 402 - 
2010 256 362 
2011 219 267 
2012 - 261 
Table  2.0: Number of participants per sampling from different seasons between 
October 2009 and April 2012 
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From the table above, during the rainy season (October 2009-2011), there 
were 402, 256 and 219 individuals respectively, while for the dry season there were 
362, 267 and 261 individuals respectively. The percentage of men were slightly less 
than women (Table 2.1) in each sampling period. This was due to men spending more 
time at work outside the village than women.  
 
Seasons 
 
Year 
Participants 
Median 
Age(years) 
Age Range 
(years) 
Male (%) 
Reference 2000 1561 14 (6-30) 0-90 50.5 
Rainy 
(October) 
     
2009 402 11 (5-28) 1-89 46.5 
2010 256 15 (9-37) 1-90 53.1 
2011 219 13 (6-33) 1-74 48.4 
Combined data 877 13 (6-31) 0-90 48.9 
      
 
 
Dry (April) 
2010 362 14 (5-34) 1-78 44.8 
2011 267 15 (7-33) 0-77 44.9 
2012 261 13 (7-37) 1-78 45.6 
Combined data 890 14 (6-35) 0-78 45.0 
 *modified from Geiger et al.,(2013) 
Table 2.1 : Demographic data related to participants in October 2000 vs 
October 2009-April2012 
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2.4 Data and samples collection 
The research team invited the participants to an evening meeting at the village 
Bourasso Department before the study was conducted to explain the procedures. The 
evening before each sampling, households were invited according to the randomized 
list for the next day. A random list of all households in the village was generated using 
the from the HDSS. Trained personnel delivered a short briefing and introduced the 
purpose of study and described the study design, after which participants or the 
parents of minor participants returned their written consent to the research team. 
Nurses or trained personnel recorded anthropometric data such as size and weight of 
the children. Temperature and respiratory rate was also recorded. 
From each participant, two drops of blood were obtained from a finger prick. 
A blood smear was prepared and another drop of blood was dropped on a filter paper 
(GenoCard of Hain Lifescience, Germany or Whatman Paper 3mm chromatography 
filter paper by Brent Fort, United Kingdom) for further molecular analysis in the 
laboratory. The filter paper was dried, packed in plastic bags and dispatched to 
Department of Infectious Disease, Parasitology Unit Heidelberg, Germany and stored 
at room temperature. 
Thin and thick smears were fixed with methanol and stained with Giemsa. A 
trained lab personnel analyzed the blood smears as per a standard protocol (Trape, 
1985). The parasite density per 200 leukocytes of parasite-positive slides were 
determined and the parasite load per microliter by multiplying by 40. The assumed 
standard count was 8000 leukocytes per microliter of blood. 
Each patient was examined by a physician and recent drug history was taken. 
All participants exhibiting the symptoms of malaria were treated with a drug 
combination of AQ-artesunate (AQ-AS) according to the guidelines of the Health 
Ministry of Burkina Faso. Additionally, trained personnel drew 5.0 ml of venous blood 
from positive patients and transported the blood samples to the laboratory after 2-5 
hours. Serum was pipetted out under sterile condition in two aliquots and kept at -80 
° C. Serum and frozen parasites were transported on dry ice by DHL Express to 
Heidelberg. After the samples arrived, all were stored at -80 ° C. 
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2.5 Materials 
2.5.1 Lab Equipments 
Table 2.2 List of equipments 
 
Equipments Model Company 
Analytical balance  Sartorius, Göttigen, Germany 
Autoclaves ABT 120-5DM Kern & Sohn, Balingen, Germany 
 2540 EL Tuttnauer, Breda, The Netherlands 
Centrifudges Biofuge fresco Heraues Instruments, Hanau, 
Germany 
Biosafety cabinet Herasafe Thermo Fisher Scientific, Dreieich, 
Germany 
 SterilGrad Class II The Baker Company, Sanford, ME, 
USA 
 Biofuge pico Heraues Instruments, Hanau, 
Germany 
 Megafuge 1.0R Heraues Instruments, Hanau, 
Germany 
 Megafuge 1.0R Heraues Instruments, Hanau, 
Germany 
 Microcentrifudge 20 Hettich, Tuttlingen, Germany 
Electrophoresis power 
supply 
Power Pac 300 Bio-rad, München, Germany 
 Power Pac 200 Bio-rad, München, Germany 
 EPS 1001 Amersham (GE Healthcare), 
München, Germany 
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 EPS 3501 Amersham (GE Healthcare), 
München, Germany 
Freezer -20˚C LGex 3410 Mediline Liebherr, Biberach, Germany 
Freezer –80˚C HERAfreeze Thermo Fisher Scientific, Dreieich, 
Germany 
Fridge LKexv 3910 Mediline Liebherr, Biberach, Germany 
Heating Block Neoblock Mono 1 Neolab, Heidelberg, Germany 
Ice Machine  Ziegra, Isernhagen, Germany 
Incubator Hereaus B12/UB12 Thermo Fisher Scientific, Dreieich, 
Germany 
Liquid Nitrogen Tank MVE Crosystem 
6000 
Thermo Fisher Scientific, Dreieich, 
Germany 
 LS 6000 Taylor-Whatson, Husum, Germany 
 RS Series Taylor-Whatson, Husum, Germany 
Liquid scintillation 
scanner 
LS6000IC Beckman Coulter, Krefeld, Germay 
Magnetic sorter VarioMACS Miltenyi Biotec, Bergisch 
Gladbach, Germany 
Magnetic stirrer RCT IKA, Staufen, Germany 
 COMBIMAG RCH IKA, Staufen, Germany 
 HR 3001 Heidolph, Schwabach, Germany 
Microscope (Light) Leica DMIL Leica, Wetzlar, Germany 
Microwave oven R94094ST Sharp, Hamburg, Germany 
MiliQ water system Purist Ultrapure Rephile, Germany 
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Particle counter Z1 Beckman Coulter, Krejel, Germany 
pH meter pH 7110 WTW, Weilheim, Germany 
Pipetmen P2 Gilson, Limburg an der Lahn, 
Germany 
 P20 Gilson, Limburg an der Lahn, 
Germany 
 P200 Gilson, Limburg an der Lahn, 
Germany 
 P1000 Gilson, Limburg an der Lahn, 
Germany 
Pipetus Forty/Standard Hirschmann, Eberstadt, Germany 
Plate reader Floustar OPTIMA BMG Labtech, Ortenberg, 
Germany 
PyroMark Q96 ID Biotage/Qiagen, Hilden, Germany 
Spectrophotometer UVIKON 923 Kontron Instruments, Munich, 
Germany 
Puncture  Hain Lifescience, Nehren, 
Germany 
Thermocycler Labcycler Sensoquest, Göttingen,  Germany 
 Gradient T Biometra, Göttingen, Germany 
UV Table UV Transilluminator Gibco BRL, Karlsruhe, Germany 
Vacuum Prep Tool  Biotage/Qiagen, Hilden, Germany 
Vacuum Workstation PyroMark Q96 Qiagen, Hilden, Germany 
Vortex Genie 2 Roth, Karlsruhe, Germany 
Waterbath 7A Julabo, Seelbach, Germany 
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2.5.2 Software 
Table 2.3 List of softwares 
 
Software Company 
JabRef 2.10 www.jabref.org 
MS Excel 2010 Microsoft Corporation, CA, USA 
MS Powerpoint 2010 Microsoft Corporation, CA, USA 
MS Word 2010 Microsoft Corporation, CA, USA 
Sigma Plot 11 Systat Software Inc., IL, USA 
Stata 11 StataCorp, TX, USA 
 
2.5.3 Consumables 
Table 2.4 List of consumables 
Consumables Company 
96 well plates Greiner Bio One, Frickenhausen, 
Germany 
96 well microtiter plates with V-bottom  Greiner Bio One, Frickenhausen, 
Germany 
96 well plate with fixed frame Axon, Kaiserslautern,Germany 
96 well pyrosequencing plates Qiagen, Hilden, Germany 
Accu-CheckSafe-T-Pro Plus Roche Diagnostics, Mannheim, Germany 
Adhesives film Axon, Kaiserslautern, Germany 
Aluminium foil Carl Roth, Karlsruhe, Germany 
Cryovials Nalgene, Wiesbaden, Germany 
Disposable gloves Hartmann, Heidenheim, Germany 
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Disposable syringes 10 ml Beckton Dickinson, Heidelberg, Germany 
Eppendorf combi tips 2.4ml u. 0.5 ml Eppendorf, Germany 
Falcon tubes Corning Incorporation, Bodenheim 
Genocard  Hain, Lifescience, Nehren, Germany 
Nitrile Disposable Gloves Semperit, Austria 
Immersion Oil Zeiss, Jena, Germany 
Slides Marienfeld, Lauda-Königshofen, Germany 
Pasteur Pipettes Roth, Kalrsruhe, Germany 
PCR tubes 0.2 ml and 8 –tube strips Axon, Kaiserslautern, Germany 
Petri dishes (10 cm diameter) Greiner Bio-One, Frickenhausen 
Petri dishes (25 cm diameter) Greiner Bio-One, Frickenhausen 
Pipette tips  Corning, Kaiserslautern, Germany 
Plastic pipettes (1 ml; 2 ml; 5 ml; 10 ml; 25 
ml)  
Corning, Kaiserslautern, Germany 
Polypropylene tubes (14 ml)  Greiner Bio-One, Frickenhausen, Germany 
Whatman paper (3mm) chromatography 
filter paper 
 
Brent Fort, United Kingdom  
 
  
2.5.4 Biological Kits 
Table 2.5 List of biological kits 
Kits Company 
DNeasy Blood & Tissue kit QIAGEN, Hilden, Germany 
PCR Purification Kit QIAGEN, Hilden, Germany 
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2.5.5 Chemicals 
Most chemicals used in this study were obtained from several companies as described 
below: 
 AppliChem GmbH 
 Amersham Pharmacia Biotech Europe GmbH 
 Boehringer JT Baker 
 Thermo Fisher Scientific ( including their trademarks Gibco, 
Invitrogen) 
 Carl Roth GmbH 
 Sigma-Aldrich (including their trademarks  Fluka) 
 Merck  
 VWR International 
  Fresenius Medical Care  
Radioactive chemicals used this study were purchased from the following companies: 
 GE Healthcare  
 [3H]-CQ (Reactivity :25 Ci/mmol , Conc: 1 mCi/ml) 
 [3H]-AQ (Reactiviy: 22.2 Ci/mmol, Conc: 1 mCi/ml) 
 
2.5.6 Biological Materials 
Table 2.6 List of biological materials 
Biological materials Name Company 
Enzymes Taq DNA 
polymerase  
Euro Clone Genomics, Italy 
Marker GeneRuler ™ 1 Kb 
DNA Ladder Plus 
Ambion - Thermo Fisher Scientific, 
Dreieich, Germany 
 
All oligonucleotides used in this study were purchased from Thermo Fisher Scientific 
   Table 2.7 : List of oligonucleotides  
Primer Sequence 5’ – 3’ 
Species –specific PCR 1 
rPLU 6 CCTGTTGTTGCCTTAAACTTC 
rPLU 5 TTAAAATTGTTGCAGTTAAAACG 
FAL 1 TTAAACTGGTTTGGGAAAACCAAATATATT 
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FAL 2 ACACAATGAACTCAATCATGACTACCCGTC 
MAL 1 ATAACATAGTTGTACGTTAAGAATAACCGC 
MAL 2 AAAATTCCCATGCATAAAAAATTATACAAA 
OVA 1 ATCTCTTTTGCTATTTTTTAGTATTGGAGA 
OVA 2 GGAAAAGGACACATTAATTGTATCCTAGTG 
Pyrosequencing  PCR of Pfcrt  
Pfcrt- CF5C-Biotin B2 - AATTCAAGCAAAAATGACGAGCG 
Pfcrt - CB10B- rev CGGATGTTACAAAACTATAGTTACC 
Pfcrt - Seq primer 76T - seq  GTTCTTTTAGCAAAAATT 
1 modified after Snounou et al., 1993 
2 B represents a biotinylation at the marked position 
 
Table 2.8 List of parasite strains 
    
Parasites Strains Origin 
P. falciparum DD2 Clonal line from Indochina (Guinet et al., 1996) 
P. falciparum HB3 Clonal line from Honduras (Bhasin and Trager, 
1984) 
P. falciparum GB4 Clonal line from Ghana (Sullivan et al., 2003) 
 
 
2.5.7 Buffers, Media and Solution  
   Table 2.9 List of buffers, media and solutions 
Buffers/Media /Solutions Composition 
Annealing Buffer (Pyrosequencing) 20 mM Tris  
 2 mM magnesium acetate  
 Set pH to 7.6 with HCl and autoclave  
Binding Buffer (Pyrosequencing) 10 mM Tris  
 2 M NaCl  
 1 mM EDTA  
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 Set pH to 7.6 with HCl and autoclave  
 Add 0.1% Tween 20 
Borate Buffer 0.2 M acid boric 
 100 ml 0.1N NaOH 
Complete RPMI/HEPES Medium 10% human serum  
 0.2 mM hypoxanthine  
 0.002% (w/v) gentamicin  
 in RPMI/HEPES medium  
Denaturation Solution (Pyrosequencing) 0.2 M NaOH 
DNA Loading Buffer (6x) 60% glycerol  
 60 mM EDTA  
 0.25% Bromophenol blue  
Ethidium bromide 1% solution in water (10 mg / mL) 
Homidiumbromid, 
3,8-diamino-5-ethyl-6-
Phenylphenanthridinium bromide 
Freezing solution 6.2 M glycerol  
 0.14 M sodium lactate  
 0.5 mM KCl  
 Set pH to 7.2 with NaHCO3 pH 9  
 Sterilize by filtration  
Glucose 360 g α- D-glucose/ L in ddH2O 2M 
Sterile by filtration 
stored at -20 ° C 
Lysis buffer for IC50 20 mM Tris-HCl pH 7.4  
 5 mM EDTA  
 0.008% (w/v) saponin  
 0.08% (w/v) triton X-100 
MACS buffer 2 mM EDTA  
 1 x PBS  
 Autoclave  
 Add 0.5% (w/v) BSA prior to use 
Mobile phase (HPLC) ACN (15%) : TEMED Buffer (85%) 
Protein lysis buffer for P. falciparum 0.07% (w/v) saponin in PBS  
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 Protease inhibitors  
Sorbitol 5% (w/v) D-sorbitol in ddH2O 
 Filter sterilized 
Thawing solution I 12% (w/v) NaCl  
 Autoclave  
Thawing solution II 1.6% (w/v) NaCl  
 Autoclave  
Thawing solution III 0.9% (w/v) NaCl  
 0.2% (w/v) glucose  
 Sterilize by filtration  
TAE buffer 4 mM TRIS/acetate 
 1 mM EDTA pH 8.0 
TE buffer 10mM Tris pH 8.0 
TEMED buffer 1.5 ml of (-N,N,N,N-Tetramethyl-
ethylene diamine 
 900 ml dH2O 
 adjust pH to 3.5 with H3PO4 
 Make up to 1000 mL 
 1mM EDTA 
TKM1 buffer 10 mM Tris pH 7.6 
 10 mM Potassium Chloride 
 10 mM Magnesium Chloride 
 2 mM EDTA 
 In 500 ml ddH2O 
TKM2 buffer 10 mM Tris pH 7.6 
 10 mM potassium chloride 
 10 mM magnesium chloride 
 2 mM EDTA 
 0.4 M sodium chloride 
 In 200 ml ddH 2 O 
Wash buffer (pyrosequencing) 10 mM Tris  
 Set pH to 7.6 with HCl and autoclave  
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2.6 Methods:  Culturing P. falciparum parasites  
2.6.1 In vitro cultivation of laboratory strains and field isolates 
Cultivation work was performed under a laminar flow (biosafety cabinet) to 
prevent contamination by organisms such as bacteria and yeast. Intraerythrocytic 
stages of P. falciparum were grown continuously in vitro as described by Trager & 
Jensen (1976). In this study, Dd2 (resistant) and HB3 (sensitive) strains were cultured 
and used as reference parasites. Regularly, all parasites were grown at 37˚C in 10 cm 
diameter petri dishes containing a final volume of 15ml of HEPES-buffered RPMI 
supplemented with 5-10% heat–inactivated A human serum (optional 5% albumax), 
200 µM of hypoxanthine, 0.2 µg/ml gentamycin and 3-4% hematocrit of group A 
erythrocytes. Cultures were maintained under controlled atmospheric conditions: 5% 
O2, 3% CO2, 92% N2, and 95% humidity. Parasitaemia was determined by preparing 
Giemsa-stained blood smear and the cultures were maintained between 1- 5 % to 
ensure optimal growing conditions. The cultures were monitored every 1-3 days, the 
medium was changed once parasitemia reached 5-10% and the cultures were split to 
avoid accumulation of toxic metabolites.  
At the study site, we withdrew blood from participants via venipuncture, which 
was kept in a blood collection tube containing EDTA, an anti-coagulant to prevent 
blood from clotting. Blood was allowed to settle for 30 minutes to separate into 
plasma and cellular components. 1.0 ml was removed from the cellular phase and 
twice of the cellular volume of  freezing solution was added.   
Field isolates from the participant blood samples were cultured and grown 
differently. The blood group of the participants were not known, therefore, AB serum 
was used in the medium to avoid agglutination . A mixture of 25ml AB and 25.0 ml 
Albumax were added with other supplements as described. 6.0 ml of this serum was 
added to a 5.0 cm diameter petri dish. Each newly cultured sample was checked every 
2 days and if the parasites appeared (either as rings or trophozoites) the culture was 
maintained until the parasitemia increased to 2-3%. Whole cultures were 
subsequently divided into two small 5.0 cm petri dishes and fresh medium was added 
to a final volume of 6.0 ml at 3.5 % hematocrit. One small culture plate was frozen 
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down for future used while the other plate was transferred to a 10 cm petri dish and 
made up to a final volume of 14.0 ml at 3.5 % hematocrit. 
 2.6.2 Preparation of Serum and erythrocytes 
Human serum and erythrocytes were vital components in the medium used to 
cultivate Plasmodium sp. In this project, all serum and erythrocytes were received from the 
German Red Cross bank, Heidelberg. Human serum was aliquoted into 50 ml falcon tubes, 
prior incubation 800 µL of 1 M CaCl2 was added and then incubated for 30 mins at 37˚C 
overnight. The following day, the tubes were centrifuged at 4000 rpm for 30 mins to pellet the 
fibrin and incubated for 30 mins at 56˚C to inactivate the serum. Later, the serum was stored 
at -20˚C until required. The blood received was aliquoted into 50 ml falcon tubes and 10 ml 
RPMI medium was added to each tube. Then, the tubes were centrifuged at 2300 rpm for 4 
mins without any interruption (brake) and finally, kept at 4˚C and used within 2 weeks. 
2.6.3 Freezing and thawing P. falciparum 
Parasite cultures were frozen in liquid nitrogen in 1.5ml cryovials to store 
laboratory strains and field isolates for future used. Successful freezing of P. 
falciparum requires approximately 2- 5% parasitemia at the ring stage to ensure the 
parasites survive the freezing and thawing procedure. A culture on a 10 cm petri dish 
was resuspended, transferred to a 15.0 ml falcon tube and centrifuged at 1900 rpm 
for 2 mins at RT. The supernatant was discarded and 1/3 of the pellet volume of 
freezing solution was added drop by drop and mixed gently. The mixture was divided 
equally and distributed into two cryovials which were finally stored at -80˚C or in liquid 
nitrogen. 
Meanwhile, when new laboratory strains or field isolates were required, a 
frozen sample was taken from the liquid nitrogen tank or -80˚C and warmed to RT. 
200 µL of thawing solution I (12% Nacl) was added and dropped gently and transferred 
to a 15.0 ml falcon tube. Then, 9.0 ml of thawing solution II (1.6% NaCl) was added 
dropwise with a gentle shake. The solution was later centrifuged at 1900rpm for 2 
mins at RT and the supernatant was discarded. Finally, 7.0 ml of thawing solution III 
(0.6% NaCl, 0.9% Glucose) was pipetted dropwise. The solution was later centrifuged 
again under the same conditions, the supernatant was removed and the pellet was 
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resuspended with 14.0 ml of complete RPMI medium and 0.5 ml of blood was added 
to the medium. The culture medium was refreshed every two days . 
2.6.4 Synchronization of P. falciparum  
Synchronization was performed when parasites at the ring stage were required 
for IC50 and drug uptake assays. The parasites were synchronized using 8.0 ml of pre-
warmed 5% sorbitol as described previously by Lambros and Vanderberg (1979). The 
solution was incubated at 37˚C for 5 mins. After incubation, the solution was 
centrifuged at 1900 rpm for 2 mins and the supernatant was discarded. The pellet was 
resuspended again in 14.0 ml of complete RPMI medium and transferred to an empty 
petri dish. This sorbitol lysis technique osmotically destroys the tubule-vesicular 
system of trophozoites and schizonts which are absent in ring stages (Lambros & 
Vander Berg, 1979). To obtain a synchronous culture, the procedure was carried out 
in the morning and evening of the same day, and repeated after 2 days. A stable 
synchronous culture could only be achieved through weekly synchronization. 
2.6.5 Giemsa staining and determination of parasitaemia 
Approximately 50µL of blood was obtained from the bottom of the culture 
petri dish by using a 1.0 ml sterilized plastic pipette. A thin smear was prepared on a 
glass slide, air-dried for 30 sec, fixed with 100% methanol and stained with 10% 
Giemsa solution for 10 to 20 minutes (Fleischer, 2004). Later, the slides were washed 
with water and observed under an immersion oil objective with a 1000x magnification 
using a light microscope. The parasitaemia is defined as the percentage of parasite-
infected red blood cells (counted iRBC from 1000 RBC). 
2.6.6 Magnetic Cell Sorting (MACS) Purification 
Purification of P. falciparum trophozoite and schizont stages was 
conducted using a MACS system. Enrichment of these stages was based on 
the paramagnetic properties of the hemozoin crystal in the parasite food 
vacuole, a product of parasite haem metabolism (Ribaut et al., 2008). 
Hemozoin-containing parasites were retained by metal wool in the column 
due to the magnetic force, while the infected red blood cells bearing ring-
stage parasites were washed away.  
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 The column was washed twice with MACS buffer and inserted into the 
VarioMACS separator. Then, the cultures were resuspended slowly and applied to the 
top of the column gradually by adjusting the stopcock to 1 drop per 3 sec. The MACS 
buffer was added until the flow is clear and the column was removed from the 
separator. The retained cells were eluted using 10 ml of MACS buffer and the eluate 
was centrifuged at 1900 rpm for 2 mins. Finally, the pellet was resuspended with 
specific buffer according to further experiments.  
 
2.7 Other Methods 
2.7.1 Determination of Amodiaquine (AQ) and Desethyl-Amodiaquine (DQ) in 
Serum 
Chromatography was performed at ambient temperature at the Department 
of Pharmacology/Epidemiology, University Hospital Heidelberg. The chromatographic 
system consisted of a gradient pump and detector. Sample injections were performed 
on an injector with a 20 ul sample loop. The mobile phase consisted of Acetonitrile-
TEMED buffer (15:85 [v/v] adjusted with ortho-phosphoric acid, H3PO4 to  pH 3.5. 
Chromatographic separation was achieved by C18 column ( 25cm by 5µM inside 
diameter). The effluent column was monitored with a detector at 340 nM. The 
detector output was linked to a Hewlett Packard computer and software was used to 
analyze and record the chromatogram. 
Stock solutions for AQ and DQ were prepared containing 1mg/ml of the drug 
and internal standard (IS) (2(7-Isoquinolinyl-ethanol) at a concentration of 1mg/ml in 
methanol. Working solutions at different concentrations were produced from the 
stock by serial dilution with dH2O. The standard concentrations of AQ and DQ were 
prepared at 20, 40, 100, 250, 650, 1350 and 2000 ng/ml. Additionally for quality 
control, the solutions were prepared separately from the standard reference of AQ 
and DQ. 250 µL blank serum was spiked with the QC solutions to obtain QC sample 
concentrations for both drugs at 60, 775 and 1600 ng/ml. All serum samples were 
stored at -20˚C until analysis and thawed at room temperature before use. 
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Later, IS (25 µL of 0.5 µg/ml) was added to all 250 µL of thawed serum in screw-
cap 15-ml polypropylene tubes, including to the standard solutions and QC samples. 
0.5 ml of borate buffer at pH 10 was added to the sample mixture. The tubes and 
content were vortexed for 30s, then 50 ml TBME was added and fixed to a tumbling 
machine for 20s before centrifuging at 3000 x g for 10 mins at 15 ˚C. 45 ml of 
supernatant containing the organic solution was transferred to a new tube and 
aspirated under nitrogen gas for 25 mins at 40˚C. The residue was reconstituted with 
200 µL of eluent (85% TEMED: 15% ACN) and sonicated for 2 mins, then 50 µL aliquot 
was injected to the HPLC system. 
Calibration curves were prepared from the standard solutions (calibrators), 
drug-free serum spiked with the drugs to obtain concentration from 10 to 2000 ng/ml 
of the AQ and DQ. Freshly prepared calibrators were used during each sample analysis 
and the replicates were included. The calibration curve was constructed by plotting 
the peak area ratio of each analyte (AQ and DQ) to the IS against the corresponding 
concentration to evaluate the linearity (Appendix 1.0). The concentration of each 
drug, AQ and DQ, in the samples was calculated using the equations from the 
constructed calibration curve.   
2.7.2 Genomic DNA (gDNA) isolation 
P. falciparum genomic DNA was obtained using two protocols from the blood 
cultures: filter paper or Genocard. The first protocol was using DNeasy Blood and 
Tissue Kit (Qiagen) and the second protocol was an alcohol-based precipitation 
method. The methods are discussed briefly below: 
Method 1 : gDNA extraction from blood culture (Alcohol-based precipitation) 
The gDNA was extracted from a culture (35.0 ml, parasitemia 3-5% 
trophozoites, 3.5% hematocrit), resuspended and transferred into a 15.0 ml falcon 
tube. It was recommended to use parasites at the trophozoite and schizont stage, as 
these lead to greater DNA yield compared to parasites at the ring stage. The first step 
was to lyse the erythrocytes, each falcon tube was centrifuged at 1900 rpm at 2 mins. 
The supernatant was discarded and the pellet was resuspended with 15.0 ml of TKM1 
buffer. 150 µL 10% of Saponin was added to lyse the erythrocyte membrane and 
  Material and Methods 
38 
 
incubated for 5 mins on ice. Then the tubes were centrifuged at 3800 rpm for 8 mins 
at 4˚C in a pre-cooled centrifuged. The supernatant was decanted and pellets were 
redissolved again in TKM1 with equal volume as before. Finally, this was re-centrifuged 
as previously described and the pellet was kept at -20˚C until needed. 
To obtain the gDNA, 150 µL of TKM1 was added to the frozen parasite pellet. 
The mixture was vortexed, then 2.4 ml of TKM2 was added followed by 150 µL 20% 
SDS. The mixture was vortexed again and incubated for 15 mins at 56 ˚C. The mixture 
was transferred to a 12.0 ml centrifuge tube (Greiner Polypropylen-12-75 centrifuge 
tube) and 1.35 ml 4M NaCl was added. The suspension was mixed thoroughly and then 
centrifuged at 11500 rpm for 10 mins at 4˚C (Beckman JA 20.1 rotor). The supernatant 
was collected to another new tube and two volumes of 100% ethanol was added. The 
tube was mixed by inverting repeatedly before it was kept for overnight at -20˚C. The 
next day, the tube was centrifuged at 11500 rpm for 30 mins at 4 ˚C. The pellet was 
obtained and washed with 500 µL of 70% ethanol and centrifuged for 5 mins. Finally, 
the DNA pellet was resuspended in water or TE buffer and transferred to a 1.5 ml 
Eppendorf tube and stored at -20˚C. 
Method 2 : gDNA extraction from blood culture (DNeasy Blood Tissue Kit) 
The gDNA was extracted, purified and dissolved in the same volume as in 
Method 1, using the DNeasy Blood Tissue Kit (Qiagen). The medium culture was 
divided and transferred into two different 15.0 ml tubes. Each tube was centrifuged 
at 1900 rpm for 2 mins. The pellet was resuspended in 10 ml of 1X cold PBS and lysed 
with saponin (final concentration 0.1% w/v) for 5 mins on ice. After 10 mins 
centrifugation at 4000 rpm at RT, the supernatant was discarded while the pellet was 
washed twice with cold PBS. The parasite gDNA was obtained by following the 
instruction of manufacturer. Briefly, the pellet was lysed with lysis buffer and 
proteinase K. Then 200 µL of 100% ethanol was added to precipitate the DNA. gDNA 
was separated from the contaminants by specific binding to silica-based membrane in  
high concentrations of chaotropic salt. Eventually, the samples were loaded onto a 
DNeasy spin column and centrifuged (8000 rpm, 1 min, RT). Washing steps were 
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performed twice and the gDNA was eluted with elution buffer or water and kept at -
20˚C. 
Method 3 : gDNA extraction from filter paper (modified from Plowe & Wellems, 
1995) 
Three to five punched holes of Whatman filter paper or Genocard containing 
blood sample were transferred to a 1.5 ml Eppendorf tube. To avoid contamination, 
the puncture was cleaned by pressing three times on a filter paper at a clean spot 
without blood sample, prior to punching new samples. Then 1.0 ml 1X PBS and 50 µL 
10% Saponin were added followed by incubation overnight at 4˚C. The following day, 
the tubes were centrifuged at 10,000 rpm for 1 min and the supernatant was 
discarded. Washing was performed by the addition of 1.0 ml 1X PBS, followed by 
centrifugation after one hour incubation at 4˚C. The supernatant was decanted and 
the small punches of filter paper were soaked in 100 µL of ddH2O.  
Subsequently, 50 µL of 20% Chelex was added to the tubes and the suspension 
was vortexed prior to incubation at 95˚C for 10 mins. The tubes were vortexed every 
2 mins. After incubation, DNA was obtained from the supernatant and purified twice 
by centrifugation at 13000 rpm for 10 mins. Ultimately, the supernatant was 
transferred to a new Eppendorf tube and the gDNA was stored at -20 ˚C until further 
requirements.  
 
2.7.3 Identification of Plasmodium sp by PCR 
The genome of P. falciparum contains highly polymorphic regions that may be 
PCR amplified and used to identify the strains (Su et al., 1999). The identification of 
different Plasmodium sp was performed based on the method described by Snounou 
et al., 1993. Nested PCR was applied on the different genes coding for the small 
ribosomal subunit RNA (ssRNA) to identify the parasite.  
The PCR reaction involved several steps where initially denaturation took place 
between 94˚C-95˚C. Then during annealing, the temperature was lowered to allow the 
DNA primers to attach to the template DNA between 50˚C to 60˚C. Finally, the DNA 
  Material and Methods 
40 
 
strand was elongated by Taq polymerase enzyme at a higher temperature and the 
process repeated between 25 to 40 cycles to yield higher DNA copies each time. In this 
experiment, the first amplification was to amplify the genus specific portion and later 
the fragments produced were added to three different specific primers for P. 
falciparum, P. malariae and P. ovale under the second PCR reaction. If a particular type 
of species was present in the sample, the primers would bind and the fragment would 
be amplified. In the table 2.10 below, two amplifications were carried out. 
 
PCR 1                                                  (µL) PCR 2                                                        (µL) 
ddH2O 17.25  ddH2O 17.25  
Euro Taq buffer (10x)   2.5  Euro Taq buffer (10x)   2.5  
Magnesium Chloride (50 mM)   1.25  Magnesium Chloride (50 mM)   1.25  
dNTPs (10 mM)   1.5  dNTPs (10 mM)   1.5  
Primer rPLU5 (50 µM)   0.5  Primer FAL1/OVA1/MAL1 (50 µM)   0.5  
Primer rPLU6 (50 µM)   0.5  Primer FAL2/OVA2/MAL2 (50 µM)   0.5  
Euro Taq polymerase (5 U/µL)    0.5  Euro Taq polymerase (5 U/µL)   0.5  
g DNA template   1.0  Sample from PCR1   1.0  
Total  25.0  25.0 
Program PCR1  Program PCR 2  
95˚C                        5 min  95˚C                        5 min  
94˚C                        1 min  94˚C                        1 min  
58˚C                        1 min  58˚C                        1 min  
68˚C                        1 min  68˚C                        1 min  
68˚C                        1 min  68˚C                        1 min  
4˚C                          ∞  4˚C                          ∞  
 
Table 2.10 : PCR reactions and thermocycler program for parasite identification 
After completion, the DNA fragments size were verified and visualized using a 
method called electrophoresis as described in section 2.7.3.1. Each parasite species 
showed a different band size: P.falciparum (205 bp), P. ovale (800 bp) and P. malariae 
( 144 bp). All samples collected between the sampling period (Oct 2009 – Apr 2012) 
25 cycles 30 cycles 
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were analyzed to investigate the prevalence of malaria at the study site and identify 
the Plasmodium species involved in the disease transmission. 
2.7.3.1 Agarose Gel Electrophoresis 
The amplified DNA can be separated according to the fragment size and 
verified by agarose gel electrophoresis. An electric field was generated in the gel 
matrix, causing negatively charged DNA to migrate to the anode. The agarose gel was 
dissolved to a final concentration of 2% (w/v) with 1X TAE buffer. Amplified DNA 
fragments were stained using EtBr to a final concentration of 1 ug/ml agarose and the 
mixture was poured onto a casting chamber with combs and left to polymerize. 
Intercalation of EtBr with DNA permits its visibility under UV light (254-366 nm). Prior 
to loading into the gel pocket, 2.0 µL of loading buffer was added to 8.0 µL of the 
amplified products. As a marker, the GeneRuler 1 kB plus DNA ladder was loaded in 
parallel with the samples. Electrophoresis was performed at a constant voltage in 1X 
TAE (30 ml gels maximum 90 V, 150 ml gels maximum 140 V). Finally, the gel was 
visualized under UV light (Gibco BRL, UV transilluminator; 260-360nm) and was 
photographed with a digital camera. 
2.7.4 Pyrosequencing 
Drug resistance is caused by point mutations in important plasmodial genes. 
The wild-type or sensitive strains and resistant strain parasites can be distinguished 
through these polymorphisms. One method to identify which allele of a marker gene 
a parasite is expressing is to study the specific gene fragment containing distinguishing 
polymorphisms.  
Pyrosequencing is a DNA sequencing technique that is based on the detection 
of released pyrophosphate (PPi) during DNA synthesis. It has emerged as a new 
sequencing methodology and is widely applicable as an alternative technology for the 
detailed characterization of nucleic acids (Ronaghi, 2011). The technique involves four 
steps which includes PCR amplification of target DNA, single-stranded DNA sample 
preparation, single-stranded DNA template purification and nucleotide pyrosequence 
analysis. The first step was to amplify the target gene pfcrt. A part of this pfcrt 
sequence was amplified using a biotinylated primer. After amplification, single-
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stranded PCR products were necessary to allow primer extension and detection of 
nucleotide sequence with the pyrosequencer. Several washing steps were performed 
to remove excess primers and salts.  
             
 
Figure 2.1:  The biochemical reactions and enzymes involved in the generation of light 
signals by DNA pyrosequencing (Ronaghi et al., 1996). In the pyrograms, each peak 
represents a pulse of light detected in the instrument. The reaction involves ATP, 
adenosine triphosphate; ADP, adenosine diphosphate; dNDP, deoxy-nucleotidyl 
diphosphate; dNMP, deoxy-nucleotidyl monophosphate; PPi, pyrophosphate. Adapted 
from www.biotagebio.com 
 
The chemical process involves the hybridization of a sequencing primer to the 
single-stranded DNA template followed by a transferred to the pyrosequencer and 
addition of one of four dNTPs . The reaction is catalyzed by DNA polymerase. During 
the process, each successful dNTP incorporation releases a PPi. ATP sulfurylase 
converts PPi to ATP in the presence of APS. Production of ATP drives a luciferase-
mediated reaction to convert luciferin to oxyluciferin that generates visible light in 
amount proportional to the amount of ATP produced. The emission of light is detected 
by a charge-coupled device camera and represented as a peak in a pyrogram. Another 
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enzyme, apyrase, involved in the degradation of unincorporated dNTPs before the 
next dNTP is added to ensure no previously added nucleotides are incorporated into 
the growing DNA strand. 
Selection of AQ resistance isolates was based on samples that were positive or 
P. falciparum and the serum was positive with AQ or the metabolites, DQ. Detection 
of SNPs that are associated with drug resistance in the pfcrt gene were validated by 
pyrosequencing. PCR reactions were performed to amplify a part of the pfcrt fragment 
as detailed below in Table 2.11 
  
PCR Mix                                                       (µL) PCR Program 
ddH2O    31.75  94˚C 2 mins  
Euro Taq buffer (10x)       5.0  92˚C 30 sec  
MgCl2 (50 mM)       2.5  56˚C 35 sec  
dNTPs (10 mM)      1.25  62˚C 1.0 min  
PrimerF C5Fc biotinylated (5 µM)       2.0  62˚C 5.0 min  
PrimerR CB10B (5 µM)       2.0  4˚C ∞  
Euro Taq Polymerase ( 5 U/ µL)        0.5     
gDNA     *5.0     
Total     50.0    
 
Table 2.11: PCR reaction to amplify the region around the SNPs in Pfcrt amino acid 
positions 72-76 
*If the concentration of gDNA is too low the volume used was increased to 8.0 µL 
and adjust the ddH20 accordingly. 
** PCR Mix, program and primer varies slightly according to Zhou et al., 2006. 
 
Hybridization of the sequencing primer was done by adding 8.0 µL of 
sequencing primer (Table 2.11) to 40.0 µL of annealing buffer and distributed to a 
PyroMark Q96 Low plate. Then, 20 µL PCR product with 3 µL Streptavidin Sepharose 
beads and 37.0 µL of binding to make the final volume 60.0 µL was added to form a 
DNA-primer mixture to Streptavidin Sepharose beads. The mixture was transferred to 
40 cycles 
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a 96 well V-bottom plate (MT-plate) and kept for  5 mins at RT on the plate shaker. 
The plate was then heated for 30s at 80˚C. The purification of single-stranded DNA 
was performed by PyroMark Q96 Vacuum Prep Worktable using several solution 
buffers. Washing buffer, denaturation buffer and 70% ethanol were filled up at the 
worktable.  
Then, the Vacuum Prep Tool (filter probes) was washed in the ddH2O to check 
for any block filter and the Vacuum Prep Tool was lowered into the 96 well V-bottom 
plate to capture the beads. Later, the beads were washed with 70% Ethanol for 5s, 
then denaturalized by denaturation buffer for another 5s and finally washed with 
wash buffer for 5s. The Vacuum Prep Tool was turned upside down and allowed to dry 
with the vacuum switched off. Subsequently, the beads were released into the 
PyroMark Q96 Low plate containing 5.0 µM sequencing primer and annealing buffer 
with a gentle shake. Then the reagent cartridge was filled with recommended volumes 
of PyroMark Gold Q96 reagents (dNTPs, enzymes, and substrate) provided by the 
software. Ultimately, the cartridge and the PyroMark Q96 Low plate was placed in the 
pyrosequencer (PyroMark Q96 ID) on the dispensing unit. The set up and the analysis 
were conducted using the PyroMark Q96 Software v1.0. 
2.7.5 Limiting dilution assay 
The use of single parasite clones is a vital component to many malaria 
experimental studies. Techniques requiring clones include isolating parasite lines from 
field samples, genotyping, drug resistance testing and genetic manipulation (Liu et al., 
2008). In this study, to isolate AQ resistant parasites, single clonal parasite isolates 
were required to ensure accuracy and unambiguous results.  
Clonal parasites were obtained by limiting dilution in a V-bottom 96 well plate 
with an initial inoculum of 0.25 – 0.5 parasites/well. The clonal parasites can be 
observed visually after 2-5 weeks, either by microscopically or enzymatic detection 
methods (Butterworth et al., 2011). Asynchronous cultures were evaluated by 
microscopy to determine the parasitaemia of the culture. According to Bunn (2011), 
1.0 ml of suspension at 50% haematocrit contains 5 x 109 of RBC, thus the total number 
of parasites in the starting culture can be determined from the parasitaemia and the 
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haematocrit  of the culture. A suspension at a haematocrit of 2% in 10 ml of culture 
media was prepared by adding 200 µL of blood and followed by a 1:10 serial dilution 
in a final volume of 10 ml.   
The sample tubes were gently mixed by inverting repeatedly to ensure proper 
mixing. To achieve a concentration cultivation of 5 parasites per mL and 2.5 parasites 
per mL, cultures were prepared from the serial dilution containing 50 parasites per mL 
in 15.0 mL medium at 2% haematocrit. 100 µL of the suspension was aliquoted into a 
V-bottom 96 well plate and the balance was transferred to a small petri dished as 
positive control. The medium was changed every 2 days. After each week, the 
haematocrit was increased to 1% until the third week 50 µL of the culture was 
removed and 50 µL of new medium at 4% haematocrit was added.  
Normally, parasites appeared after two weeks in the positive control plate, 
followed by an increasing number of positive wells in the 96-well plates. The positive 
wells were indicated by the dark colour of blood, cloudy medium and confirmed by 
microscopy. Finally, the clonal parasites from the positive wells were transferred to a 
5.0 ml petri dish to increase the number of parasites to be frozen down and for further 
experimention. The procedure above was repeated when 75% of the 96 well plates 
were positives to confirm clonal population. 
2.7.6 In vitro drug susceptibility assays (IC50) 
The in vitro drug susceptibility assay is a research tool used for several 
purposes such as: to monitor drug resistance, drug development screening and 
validate candidate molecular markers of drug resistance. There is no single, universally 
accepted standardized in vitro assay protocol. Different research laboratories take into 
account different factors, where each can profoundly influence the drug response. 
Nonetheless, it is the gold standard to measure the effectiveness of a drug by its ability 
to inhibit parasite growth.  
In our laboratory, the method used for measuring the IC50 was adapted 
according to the standard SYBR green fluorescence-based assay (Smilkstein et al., 
2004). A range of drug concentrations were chosen based both on those previously 
described in the literature and to ensure a sufficient number of points to determine 
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the IC50. Two days prior to performing the experiments, the cultures were 
synchronized. Each sample culture was performed in triplicate to perform statistical 
analysis and tested for the drug studied (CQ, AQ and DeAQ). Each drug and 
concentration was tested in duplicate as in the scheme. The first (0% growth) and 
second (100% growth) column were used as controls while the last two columns were 
the duplicates. Parasitaemia was determined (counted iRBC from 1000 RBC) for each 
culture and adjusted to 0.5% parasitaemia at 3% haematocrit. The 96 well plate were 
prepared as in the scheme.   
50 µL of medium was pipetted into each well and 25 µL was added to the first 
row. By using a multichannel pipette, the suspension was mixed thoroughly and then 
25 µL was transferred to the second row and to the next until the last row to produce 
a 1:3 serial dilution. The last 25 µL was discarded. Later, 50 µL of prepared parasites 
were added to their respective wells to a final 1.5% haematocrit and the plates were 
incubated for 72 hours at 37˚C. After incubation, the plates were kept at -80˚C for at 
least 2 hours or until further use and thawed for 1 hour, before adding 100 µL lysis 
buffer containing SYBR Green (1.2 µL in 10 ml buffer) to each well. Then, the plates 
were shaken briefly and incubated for 1 hour at RT.  
Plate scheme: 
-ve +ve CQ1 CQ2 AQ1 AQ2 DeAQ1 DeAQ2 Drug1 Drug2 +ve -ve 
RBC* iRBC 500 nM        iRBC RBC* 
RBC iRBC 166.7nM        iRBC RBC 
RBC iRBC …        iRBC RBC 
RBC iRBC …        iRBC RBC 
RBC iRBC …        iRBC RBC 
RBC iRBC …        iRBC RBC 
RBC iRBC …        iRBC RBC 
RBC* iRBC …        iRBC RBC* 
    
   Note :the value of RBC* usually was low and not included in the average calculation 
due to strong evaporation 
   
Subsequently, the fluorescence measurements of the plates were recorded 
using the plate reader FLUOstar OPTIMA and the parameters were set as follows: 
1:3 serial dilution 
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excitation wavelength: 485 nm; emission wavelength: 520 nm; gain: 1380; 10 flashes 
per well; top optic. Calculations for each fluorescence signal were performed by 
subtracting the background (negative control RBC) from all iRBC and tested drugs. The 
growth inhibition of each drug was plotted in SigmaPlot (Version 11.0) to determine 
the IC50. 
2.7.7 Drug transport assays and measurements 
Clonal parasites were cultured prior to performing the experiments and 
synchronized using sorbitol on the previous day as described in 2.6.4. The clonal 
parasites were purified using a strong magnet (VarioMACS, Miltenyi Biotec, Germany), 
as explained in 2.6.6. This produced a purity of 98-100% trophozoite-infected 
erythrocytes and the concentration of parasites were adjusted to between 20000 – 
30000 iRBC/µL. The exact concentration was determined by a Thoma counting 
chamber and later confirmed by microscopic examination of Giemsa-stained blood 
smears. Parasites were fed at least prior starting the purification process. Magnet-
purified trophozoite-infected erythrocytes were resuspended in a pre-warmed 
reaction buffer (RPMI medium without bicarbonate). Then, the trophozoite cultures 
were incubated at 37˚C at pH7.3. The [3H]-drug (CQ or AQ/ 40 nM) was added to the 
preincubated culture and the time course was monitored. Every 5 min, 2 μl of 0.5 M 
glucose were added to the cells.  
Duplicate 75 µL aliquots from each sample were transferred at various time 
points (5´ and 20´) to a PCR tube containing 100 µL separation oil, consisting of a 
mixture of 5:4 dibutylphthalate and diocytlphthalate with an equal volume of reaction 
buffer equilibrated at 4˚C at pH 7.3 and centrifuged at 17000 xg for 1 min. The cells 
were separated from the aqueous medium which contained the unincorporated [3H]-
drug hence preventing further entry of the drug to the cells. Then 75 µL of the upper 
phase was removed from each sample and the radioactivity was determined to 
measure the extracellular [3H]-drug concentration. The cell pellets were accumulated 
at the tip of the reaction tube and recovered by cutting the tip through the oil layer 
using a scalpel. It was placed in a 1.5 mL Eppendorf tube and incubated overnight at 
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55˚C in 100 µL  of tissue solubilizer (a mixture of 2:3 of ethanol and tissue solubilizer 
from Pharmacia).  
The next day, the lysate was decolorised by the addition of 25 μL of 30% H2O2 
and acidified by adding 25 µL of 1 N HCl. The lysate was transferred to a scintillation 
vial by cutting the lid from an Eppendorf containing 4 mL of scintillation cocktail and 
measuring radioactivity on a liquid scintillation counter (TRI-CARB 2100 TR, Packard). 
The intracellular drug concentration was calculated from the amount of labelled drug 
taken up by the cells, assuming the volume of a trophozoite-infected erythrocyte is 75 
fL (Saliba et al., 1998). Drug accumulation was expressed as a ratio of the intracellular 
to the extracellular drug concentration (drugin/drugout) (Sanchez et al., 2008b). 
2.7.8 Parasite screening and quantitative recrudescence assays 
A group of random subsamples (n=200), which were positive by microscopy, 
were selected and cultured using the method described as above in section 2.6.1. The 
cultured parasites were challenged with 60 nM of DeAQ after the parasites appeared 
for two cycles. In determining the IC50 of CQ drugs, a cut-off value of 60 nM was used 
to define parasite resistance in our laboratory. Following the drug challenge test, a 
quantitative recrudescence assay was performed to inspect the occurrence of 
dormancy in AQ resistance parasites.   
The quantitative recrudescence assays test was conducted based on a method 
described by Tucker et al., (2012). A final concentration of DQ (60 nM) was added to 
15.0 ml cultures at 5% parasitaemia. After 6h post-drug exposure, the cultures were 
washed with RPMI 1640 to remove the drug. Prior to drug treatment, blood smears 
were made after 24 hours of drug exposure. Later, cultures were monitored until the 
normal morphological parasites appeared with 2.5% parasitaemia. Parasites were 
categorized as dead, dormant, ring, trophozoite or schizont. Recovery was calculated 
as the ratio of normal morphology parasites/total parasites while the ratio of 
dormant/total parasites were also calculated. Photos were taken pre-drug exposure 
and every 24h post-drug exposure. 
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2.7.9 Data and statistical analysis 
The Graphs were produced using Excel 2013 and Sigma-Plot 12.5 (Systat 
Software, Chicago, USA). Statistical analysis was performed using IBM SPSS 
Statistics 25.0 and STATA 11 program (Stata Corporation, Duxbury, USA). Two-Way 
ANOVA with Tukey’s HSD test  was used to assess the significance in differences 
between parasite clones and drugs. Pearson’s correlation was used to analyze the 
association between the drug susceptibilities.
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3.0 Results 
3.1 Prevalence of malaria cases between dry and rainy season in 2000 and 
2009-2012 
Malaria is holoendemic around the Nouna town area in Kossi 
Province of Burkina Faso, with prevalence rising during the rainy season 
(July-September) and the data is inadequate mainly in adults (Muller et al, 
2001, 2003). One of the objectives of this study was to obtain information 
regarding the prevalence of malarial infections between different seasons 
by comparing the rainy season in 2000 as a baseline to the dry and rainy 
seasons from 2009 until 2012.  
                           
 
Figure 3.0  Prevalence of malaria in Nouna, Burkina Faso between dry (April) and rainy 
(October) season from 2000, 2009-2012. A total of 1561 residents participated in the study in 
2000 during rainy season (Stich et al., 2006). The malarial infection was assessed from a 
random subpopulation (n=201) by microscopy, using Giemsa thick blood smear and by nested 
PCR from a filter paper containing blood (Snounou et al., 1993). The following study involved 
1761 participants conducted during rainy season in 2009 (n=402), 2010 (n= 256) and 2011 
(n=219) while in dry season 2010 (n=362), 2011 (n=267) and 2012 (n=261). 
 
 The malaria cases represented in Figure 3.0 showed a higher 
prevalence during the rainy season when compared to the dry season, 
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based on microscopy. In the dry season for April 2010, April 2011 and April 
2012, the prevalence varies slightly with values of 30.4%, 29.2% and 33.0% 
respectively, while in the rainy season for October 2000, October 2009, 
October 2010 and October 2011 the prevalences were 80.6%, 58.2%, 57.0% 
and 49.3% respectively. The percentage of infection by microscopy 
decreased when compared to the reference in 2000, while the prevalence 
by PCR diagnosis also showed a similar trend: higher during the rainy 
compared to the dry season.  
The PCR values were much higher compared to microscopy using 
Giemsa-stain. These results showed that the PCR method was more 
sensitive and increased the detection of prevalence to 39.3% in April 2010, 
50.8% in April 2011 and 34.6% in April 2012. Similarly, in the rainy season, 
the occurrence of malaria cases increased to 92% in October 2000, 66.1% in 
October 2009, 67.4% in October 2010 and 73.7% in October 2011, as 
measured by PCR. The increase of prevalence in the rainy season was due to 
the abundance of Anopheles mosquitoes that transmit Plasmodium sp 
compared to the dry season where the abundance of vectors were lower.  
The comparison between microscopy and PCR showed that a 
significant number of malaria cases which was also reported by Di Santi et 
al. (2004) and Oster et al., (2005) were undetected by microscopy. 
Moreover, microscopic examinations were unable to detect mixed 
infections and often underestimated the extent of infection, consistent with 
previous report (Zakeri et al. 2002). Since P. malariae and P. ovale infections 
are associated with long-term complications that require additional 
treatment, underestimating the infection could lead to a severe lapse in 
diagnosis. There was a significant difference 
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Table 3.0  Distribution of Plasmodium sp. during rainy and dry seasons as 
compared to the rainy season in 2000  
 
Year 
 
Seasons 
 
Single Infection (%) 
 
Mixed Infections (%) 
  P.f P. m P.o P.f + P.m P. f + P.o 
2000 Rainy 72.0 8.3 0.7 5.1 - 
2009 Rainy 50.0 0.4 4.1 1.7 - 
2010 Dry 41.6 0.8 0.3 - - 
 Rainy 69.6 2.7 1.6 1.4 0.3 
2011 Dry 24.0 - - - - 
 Rainy 40.0 2.8 - 1.9 - 
2012 Dry 22.0 1.2 - - - 
   
*P.f : Plasmodium falciparum    P.m : Plasmodium malaria       P.o : Plasmodium ovale 
   
Table 3.0 shows that P. falciparum was the most common 
Plasmodium species found in most seasons followed by P.malariae and P. 
ovale. In addition to single infections, the sensitivity of the PCR method 
allows co-infections to be detected between the seasons, especially P. 
falciparum and P. malariae co-infection and P. falciparum and P.ovale co-
infection. In October 2010 during the rainy season, only P. falciparum and P. 
ovale co-infection was observed at 0.3%. During the dry season in April 
2011, based on microscopy and PCR, only P.falciparum was identified in the 
samples. Another observation from the study was that the prevalence of P. 
falciparum reduced from 72% in October 2000 to 40% in October 2011 
during the rainy season. Similarly, the percentage of P. malariae also 
declined from 8.3% in October 2000 to 2.8% in October 2011 during the 
rainy season. P.ovale was not detected in any samples collected in 2011 and 
2012.
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3.2 Amodiaquine and Desethyl-Amodiaquine concentrations 
 The second objective of this study was to isolate and characterize the 
amodiaquine-resistant P. falciparum strains from Bourasso, Burkina Faso. 
The first approach used was selecting a subsample from 402 blood samples 
of the rainy season (October 2009).  
 
The concentrations of Amodiaquine (AQ) and Desethyl-amodiaquine 
(DQ) were determined by HPLC as described in 2.7.1. A calibration standard 
was prepared at 20, 40, 100, 250, 650, 1350 and 2000 ng/ml as shown in 
Appendix 2.0 and Appendix 3.0.  The peak ratio of each analyte (AQ and DQ) 
to the IS was plotted against the corresponding concentration to make 
calibration curves and determine the linearity of the method on each day of 
analysis.  
 
Regression analysis was performed using Microsoft Excel 2013 to 
determine the slope, intercept and the correlation coefficient (r) of each 
calibration curve. The concentrations of analytes were calculated using the 
equation obtained from the calibration curves. The method was validated by 
adding three Quality Controls (QC) with different concentrations that 
included the low, medium and upper range of the calibration curves. 
Furthermore, 25.0 ul of an Internal Standard (IS) (1mg/ml in methanol) was 
also added to each sample including standards and QC in order to ensure 
reliable quality and consistent results. 
 
A total of 42 serums were positive for either AQ or DQ. Of the 42 AQ 
or DQ positive samples, only 15 samples that were positive by microscopy or 
PCR, were selected for further analysis. Blood samples from 15 identified 
patients were cultured as described in 2.6.1 for in vitro culture of the 
laboratory strains and field isolates. Three laboratory strains with different 
phenotypes (HB3, DD2 and GB4) were used as reference strains in search for 
the AQ-resistant isolates from Burkina Faso. HB3 is a chloroquine sensitive 
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strain while DD2 and GB4 are chloroquine resistant strains. The cultures 
were maintained cautiously to prevent bacterial or fungal contamination.  
 
Table 3.1 Concentration of Amodiaquine (AQ) and Desethhyl-Amodiaquine (DQ) 
(ng/ml) in blood samples that were positive by microscopy.  
 
Lab strains/ 
Field isolates 
[AQ] /[DQ]/ng/mL  
in patient’s blood  
S47 <LOQ 
S6 38.85 
S9 32.5 
S79 34.29 (AQ) 
S166 50.69 
S173 LOQ 
S256 LOQ 
S278 48.03 
 
                                  ** < Limit of Quantification(LOQ) = < 24 ng/mL 
                                
Table 3.1 Concentrations of AQ and its metabolite DQ determined 
from each blood sample. From 15 cultured isolates, only eight could be 
rescued and adapted to laboratory conditions. The number denotes the 
patients ID during the rainy season in October 2009. AQ was detected in 
sample 79 (S79) at 34.29 ng/ml. In the other blood samples, concentration 
of desethyl-amodiaquine was measured at 38.85 ng/ml, 32.50 ng/ml, 50.69 
ng/ml and 48.03 ng/ml for S6, S9, S166 and S278 respectively. S47 has 
detected DQ below the LOQ and also S173 and S256, DQ was detected at 
LOQ which was at 24 ng/ml. LOQ were determined by signal-to-noise (S/N) 
ratio evaluations of analytes. It is defined as the lowest concentration of 
analyte with S/N ratio at least 10 and acceptable accuracy and precision 
(15%) (Braggio et al. 1996). 
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3.3 Single Nucleotide Polymorphisms (SNP) in the PfCRT haplotype of P. 
falciparum 
Further investigation was performed to characterize the eight 
laboratory-adapted field isolates. To amplify the pfcrt region, DNA was 
isolated from each strain and used for pyrosequencing. The primers CF5C 
and CB10B was used to amplify a region of pfcrt which includes the 
polymorphic region in exon 2. CB10B was biotinylated to detect 
polymorphisms in codons corresponding to amino acid 72 while CF5C was 
biotinylated to detect polymorphisms at amino acid position 76. The 
technique involved the quantification of a light reaction which depends on 
the amount of nucleotide fused at a specific base pair position and allows 
the allele to be determined. Mutations between acid amino acids 72 and 76 
in the polymorphic region are characterized by the haplotype CVMNK (wild-
type) and haplotype CVIET (resistant-type) with three modified bases ‘IET’. 
Below, Figure 3.1 presents examples of pyrograms produced after each DNA 
sample was analysed by this technique.
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Figure 3.1 Selected Pyrograms for pfcrt genotyping which includes DD2 and HB3 as reference 
while S9C6, S47C7 and S173D3 are the clonal lines. The haplotype was determined by reading 
the pyrogram from right to left. X-axis represents the nucleotides while Y-axis represents the 
light intensity. Height ratio referred to number of nucleotides for eg. the reference resistant 
strain DD2 consist CVIET haplotype while the reference sensitive strain, HB3 consist of CVMNK 
haplotype. 
 
 
Table 3.2  pfcrt haplotypes for eight cultured isolates (parental clones) which were 
positive for AQ in the serum including three reference strains HB3, Dd2 and GB4.  
 
                                Positions within pfcrt 
 
 
 
 
Lab strains/ 
Parental clones 
72 73 74 75 76 
S47 C V I E T 
S6 C V I E T 
S9 C V I E T 
S79 C V I E T 
S166 C V I E T 
S173 C V M N K 
S256 C V I E T 
S278 C V I E T 
HB3 C V M N K 
Dd2 C V I E T 
GB4 C V I E T 
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Table 3.3  Single nucleotide polymorphisms (SNP) analysis for clonal lines 
Clones S173 PfCRT Haplotype Clones S9 Clones S47 PfCRT Haplotype 
S173 A1 CVMNK 9A4 S47 C1 CVIET 
S173 A11 CVMNK 9 A6 S47 C7 CVIET 
S173 A12 CVMNK 9 C6 S47 D4 CVIET 
S173 B11 CVMNK 9 C9 S47 D7 CVIET 
S173 C7 CVMNK 9 D7 S47 E8 CVIET 
S173 D3 CVMNK 9 E3 S47 F8 CVIET 
S173 D10 CVMNK 9 F2 S47 G6 CVIET 
S173 E8 CVMNK 9 F11 S47 G8 CVIET 
S173 G6 CVMNK 9 H7 S47 H8 CVIET 
S173 H8 CVMNK 9 H8 S47 H10 CVIET 
 
  
 Based on Table 3.2 and Table 3.3, genotypic analysis allowed the 
determination of the pfcrt haplotype within the parental clones and clonal 
lines. The results show that all parental clones harbour the PfCRT haplotype 
CVIET except sample no. S173. No other PfCRT haplotype such as SVMNT, 
which is more prevalent in South America, Afghanistan, Iran, Laos (Sa et al. 
2009) was detected during the genotypic analysis.  
Three parental clones from the drug susceptibility assay in Figure 3.2 
were selected. The selection was based on different drug susceptibilities and 
performed in parallel with the genotyping. After limiting dilution, individual 
clones were obtained and a similar genotypic analysis conducted after which 
ten clones were selected from each parental line. All clonal lines from 
sample S173 has a similar PfCRT haplotype as the sensitive strain HB3 
(CVMNK), while clonal lines from S9 and S47 were comparable to the 
resistant strain Dd2, which harbours the CVIET haplotype. 
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3.4 Characterization of field isolates 
There are several ways to evaluate drug resistance. In vitro testing of 
P.falciparum is one of the most important tools to monitor the efficacy of 
anti-malarial drugs (Briolant et al., 2009). In this study, field isolates were 
cultured according to the method developed by Trager and Jensen 
approximately 40 years ago (Trager, 1976). Parasite susceptibility to CQ, AQ 
and its metabolites, DQ were measured using Syber Green, a fluorescent 
dye-based in vitro drug sensitivity assay. The eight field isolates which were 
serum positive for AQ or DQ were tested for resistance to AQ and CQ. 
There are wide variations in the threshold used to define in vitro 
resistance of P. falciparum to amodiaquine, probably due to the differences 
in protocols and interpretation (Echeverry, 2006). In our laboratory, the 
threshold for CQ resistant strains was estimated at approximately ≥60 nM 
while that for AQ resistant strains was estimated to be ≥ 20 nM.  The in vitro 
susceptibility of the isolates was determined using IC99, IC90 and IC50. (IC: 
inhibitory concentration). IC50 is widely used and defined as the 
concentration of the drug that inhibits the growth of 50% of the parasites as 
compared to the control without drug (Echeverry, 2006). The values were 
determined by non-linear regression analysis in which the logarithm of 
concentrations was plotted against growth inhibition. A sigmoid curve was 
fitted to the plot using the Sigmaplot 12.5 software to obtain IC50 values.  
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Figure 3.2 Drug susceptibility of the reference strain DD2, GB4 and HB3 towards CQ and AQ, 
together with the IC50 values of selected field isolates which successfully cultured in the 
laboratory condition. The data represent the mean±SEM of three to five independent 
determinations per isolates. Arrow showed the three isolates with different phenotype 
(susceptibility) chosen for further investigation. Two-Way ANOVA test was performed to check 
for differences between isolates and drug at level ***=p <0.05  
 
Figure 3.2 shows the results of IC50 values for eight field isolates with 
three reference strains (HB3, DD2 and GB4). The field samples harboured 
CQ sensitive and resistance strains when compared to the IC50 reference 
value given by HB3 (15.47±2.16) nM, Dd2 (94.26±13.23)nM and GB4 
(122.30±13.04) nM. Similarly, the AQ sensitivity values range from 4.40±1.09 
to 9.74±1.49 nM while for AQ resistance, the values range from 14.41±3.34 
nM to 19.58±0.32 nM. Three field isolates, which were S6, S9 and S47, 
showed resistance to CQ while S79, S166, S173, S256 and S278 the IC50 
values where lower than 60 nM indicating that these samples were sensitive 
to CQ.   
For the AQ drug in vitro assay, the values were 16.98nM and 
19.58nM for S9 and S173 respectively indicating resistance to AQ while the 
all other field isolates showed values below the threshold <20 nM and were 
therefore considered sensitive. Comparatively, to reference strain HB3 
which has the value of 9.21nM for AQ sensitive strain. Sample S9, S47 and 
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S173 were chosen to obtain clonal parasite lines by limiting dilution. S9 
exhibited resistance towards CQ and AQ while S47 demonstrated an 
intermediate resistance towards CQ and AQ. Lastly, S173 was sensitive to 
CQ and resistant to AQ. S9 was cultivated from a male child’s blood (4 years 
old) whose serum tested positive for DQ at 87.8 nM. Then, S47 was 
obtained from a female child of 2 years while S173 was also taken from a 
male child of 3 years of age. For both samples S47 and S173, the 
concentration of DQ was identified below the LOQ which was 65.8 nM. 
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3.4.1 Susceptibility patterns of clonal parasites 
 
            
Figure 3.3  Drug susceptibility of the S9 clonal lines  towards CQ, AQ and DQ, including the 
reference HB3, Dd2 and GB4. Ten clones of S9 were chosen from a limiting dilution assay and 
the IC50 values were obtained using the SYBR Green method. In brief, after 72 hours incubation, 
the test plate was removed and frozen down. Before measuring, the plates were thawed and 
100 uL of lysis buffer containing SYBR Green fluorescent dye was added to each well and mix 
thoroughly. Then, the plate was incubated in the dark for at least one hour. The data represent 
the mean±SEM of at least three to five independent determinations per clones. Two Way 
ANOVA test was performed for significance difference between isolates and drug at level *** 
= p<0.001 
    
The above figure shows the drug response for CQ, AQ and DQ. Ten 
clones were chosen from the parental clone S9. All clones were resistant to 
CQ when compared to the reference strain DD2. The value of the observed 
IC50 ranged from 71.8 to 215.5nM, while the IC50 value for AQ were recorded 
from 9.8 to 20.1 nM. For DQ the readings ranged from 6.25 to 18.0 nM for 
the selected clones. Most clones of S9 were sensitive to DQ. The readings 
recorded for each drug response between clones varies due to the 
difference in genetic background of each clone. The highest IC50 for CQ was 
shown by clone F911 (215.45 ± 39.72 nM), while for AQ the highest value 
was observed for clone 9C6 (20.10 ± 0.21 nM) whereas for DQ the values 
were quite low compared to the Dd2 reference strain which was recorded at 
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17.97 ± 0.58 nM. A significant variation was observed between the drugs 
and the clones using a Two Ways Anova (***= p<0.001). Between drugs, CQ 
and AQ were statistically different and also between CQ and DQ at level 
p<0.001. A clear cross-resistance was observed in clone 9C6, 9F2 and 9H8.  
The aim of this investigation was to obtain one clone that was highly 
resistant to CQ, AQ and DQ. Therefore, based on the above results, only one 
clone was selected for sample S9 which featured high drug susceptibiliy to 
CQ, AQ and DQ. Although 9C6 (CQ: 101.18 ± 3.19 nM,  AQ: 20.10 ± 0.21 nM, 
DQ: 19.97±0.58 nM) and 9F2 (CQ: 109.00 ± 22.02 nM, AQ: 18.73 ± 1.69 nM, 
DQ: 17.73 ± 1.21 nM) clones represents the closest features required only 
9C6 was selected because the variation in IC50 for CQ was lower compared 
to clone 9F2. Referring to Table 3.3, all clones were genotypically resistant 
since they harboured the pfcrt CVIET haplotype. In spite of the haplotype 
resistance, some clones showed a high response to CQ and AQ while some 
showed lower IC50 values. Surprisingly, only two clones, 9C6 and 9F2 have 
IC50 values of AQ and DQ, which were closely resistant compared to Dd2. 
The confirmation of the resistance phenotype will be studied further in the 
following drug accumulation test. Based on this study, clone 9C6 was chosen 
for further investigations since it was resistant to CQ, AQ and DQ.                                       
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Figure 3.4  Drug susceptibility of the S47 clonal lines  towards CQ, AQ and DQ, including the 
reference HB3 and Dd2. Ten clones of S47 were chosen from limiting dilution and the IC50 values 
were obtained using the SYBR Green method. The data represent the mean±SEM of at least 
three to five independent determinations per clones. Two Way ANOVA test was performed to 
determine significance between isolates and drug at level ***= p<0.001. 
                   
Figure 3.4 shows the drug response of the clonal lines of S47. Ten 
clones were selected and an in vitro assay was performed for all the clones 
towards CQ, AQ and DQ. Based on the genotyping results by pyrosequencing 
in Table 3.3, all clones from S47 harboured the CVIET haplotype. However, 
the IC50 values were mostly half of the IC50 value of CQ for Dd2. The readings 
ranged from 57.37 to 93.77 nM for CQ, while AQ ranged from 6.29 to 19.65 
nM and DQ from 5.10 to 10.91 nM. All clones were sensitive to DQ but they 
harboured the pfcrt CVIET haplotype. Nevertheless, half of the S47 clones 
were sensitive to AQ ( 47C1, 47C7, 47F8, 47G8, 47H8) and another five 
clones were resistant to AQ (47D4, 47D7, 47E8, 47G6, 47H10). The highest 
values of IC50 for CQ was recorded at 93.77 ± 3.31 nM for 47E8 and the 
lowest was 57.37 ± 1.77 nM for 47D4. There was no clear cross-resistance 
within the clones but the closest value was presented by 47E8 when 
compared to the resistant Dd2 strain (CQ : 93.77 ± 14.26 nM, AQ: 16.26 ± 
3.36 nM). The values of the drug response between clones and drugs 
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showed a significance difference at level p<0.001 when analysed by a Two 
Way Anova test. Between drugs, CQ and AQ were statistically different and 
also between CQ and DQ at level p<0.001. 
From the above results, only one clone was chosen as a candidate for 
a further characterization assessment. Interestingly compared to the S9 
clones, the S47 clones were genetically resistant but showed intermediate 
drug susceptibility to CQ when compared to the resistant strain Dd2. Clone 
47C7 was selected from this study. This clone showed a phenotype 
characterized by intermediate resistance to CQ and sensitivity to AQ and 
DQ.  
 
 
 
Figure 3.5  Drug susceptibility of the S173 clonal lines  towards CQ, AQ and DQ, including the 
reference HB3 and Dd2. Ten clones of S173 were chosen from limiting dilution and  the IC50 
values were obtained using the SYBR Green method. The data represent the mean±SEM of five 
independent determinations per clones. Two Way ANOVA test was performed for significance 
differences between isolates and drug at level ***= p<0.001. 
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Finally, the third set of clones were analysed and these clones were 
obtained from sample 173 (S173). Ten clones were chosen after a limiting 
dilution assay and tested in an in vitro susceptibility test. The parental 
clones S173 exhibited a sensitive phenotype towards CQ and DQ but were 
resistant to AQ. After the analysis was conducted, IC50 values of ten clones 
showed variation between them. There was a significant difference in the 
drug response value between clones and the drug studied at level p<0.001 
using the Two Way Anova test. Drug response of all clones were difference 
statistically compared to Dd2 but not HB3.  
The IC50 values for CQ ranged from 6.10 to 13.9 nM while those for 
AQ ranged from 4.34 to 14.20 nM. In contrast, the values for DQ were 
recorded from 2.20 to 4.88 nM. From Table 3.3, the genotypic analysis has 
shown that all clones of S173 harboured the pfcrt CVMNK haplotype similar 
to the parental strain. The CVMNK haplotype was associated with CQ-
sensitivity. The highest IC50 value recorded for CQ was by clone 173G6 at 
13.92 ± 3.52 nM and the lowest was 6.10 ± 1.06 nM. The highest value for 
the AQ drug response was recorded by clone 173D3 at 14.20 ± 2.54 nM. 
Lastly for the AQ metabolite, DQ, the highest value was shown at 4.88 ± 0.53 
nM by clone 173A11. 
In this analysis, similarly to the other clone groups, one candidate 
from the S173 clonal lines will be chosen. From the above results, a 
selection was made after several consistent results by clone 173D3. The 
phenotype of 173D3 exhibited CQ-sensitivity and intermediate resistance to 
AQ. All clones (9C6, 47C7 and 173D3) that were selected from each group 
were further investigated and analysed by studying the drug accumulation 
in the food vacuole of the parasites.   
 
3.4.2 Drug accumulation in P. falciparum 
Phenotype confirmation of the selected clones were further 
investigated. It involves the amount of drug accumulation, which is defined 
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by transport and/or partitioning processes in the food vacuole of P. 
falciparum. The parental clones HB3 and Dd2 along with the three selected 
clones chosen from the drug susceptibility test were incubated in a buffer 
containing 40 nM [3H]-chloroquine and 40 nM [3H]-amodiaquine to 
determine the amount of chloroquine accumulation at 5 mins (initial uptake 
phase) and 20 mins (early steady phase, Fig 3.6 A and C).  
The amount of CQ and AQ was expressed as a cellular accumulation 
ratio (CQin/CQout) or (AQin/AQout) given as the total amount of CQ taken up in 
5 min and 20 min, respectively from 40 nM extracellular concentration, 
divided by the residual extracellular CQ concentration. The results of these 
experiments showed that high accumulation of CQ was similar to the 
parental HB3 whereas low accumulation of CQ was comparable to parental 
Dd2.
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Figure 3.6 CQ and AQ accumulation in reference strain HB3 and DD2 along with the 
selected clones from the field isolates. A and B refer to AQ accumulation at 5 and 20 
mins time point in the HB3 and DD2 parental strains together with 9C6, 47C7 and 
173D3. While C and D refer to CQ accumulation in the the HB3 and DD2 parental 
strains together with 9C6, 47C7 and 173D3. The data represents the mean value ± 
SEM of three independent determinations per clone. A significant difference was 
observed between the clones at level ***=p<0.001 using Two Way Anova Test for 
each drug accumulation. 
   
The results of CQ and AQ for 5 min and 20 min time points are 
illustrated in Figure 3.6. It appears that clones which accumulated high level 
of CQ were susceptible to CQ while clones accumulated lower CQ were 
resistant. It was shown that 9C6 was resistant clone while 173D3 was a 
susceptible strain. From Two Way Anova analysis, there was a significant 
A*** 
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difference (***= p<0.001) between the clones tested. However in this 
experiment the parental strain (positive control), has a high variation for 
Dd2 at AQ 20 mins therefore more replicates were required to confirm the 
phenotype of the clones. Sa et al., (2009) and Sanchez et al., (2011) reported 
similar findings where based on the experimental results, susceptible clones 
accumulated higher amounts of AQ while the resistant clones accumulated 
lower amount of AQ Figure 3.6 (A and B). The driving force for parasite 
accumulation of the 4-aminoquinolines is proposed to be a transmembrane 
proton gradient sustained by a vacuolar ATPase (Hawley et al., 1999).   
 
 
 
Figure 3.7  Drug susceptibility of parental clones HB3 and Dd2 along with the 
selected clones. A and B refers to CQ IC50 and AQ IC50  respectively. The data 
represents the mean value ± SEM of three independent determinations per clone. A 
significant difference was observed between the clones at level ***=p<0.001 using 
One Way Anova Test for CQ drug susceptibility assay while for AQ only 9C6 was 
statistically different compared to other clones. 
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 Another observation reported by Sanchez et al., (2011) was that the 
AQ accumulation ratios were much higher than CQ in the progeny studied. 
Similar observations were obtained in this study but more replicates are 
needed to validate and to reduce the variations. In another study by Hawley 
et al., (1999), AQ accumulated 2-3 fold higher compared to CQ. These 
authors also described high AQ IC50 values that were associated with lower 
amounts of the drug and the two response parameters reciprocally 
correlated to each other. This supports the findings in this study where the 
drug susceptibility of CQ and AQ reciprocally correlated which means higher 
IC50 values with lower amount of drug accumulation (Figure 3.7) 
Further investigation was performed to confirm the phenotype of 
9C6, 47C7 and 173D3. We hypothesized that 9C6, 47C7 and 173D3 were 
adapted to the culture condition since it was cultured continuously for a 
longer period in the laboratory. New set of clones from 9C6, 47C7 and 
173D3 freeze downs, dated 23.12.12, 23.12.12 and 14.04.12 respectively, 
were obtained, thawed and cultured. These clones were labelled as 9C6O, 
47C7O, 173D3O where O referred to ‘recent’. After two cycles, the 
trophozoites of the older clones were used for the drug transport assay. 
Similarly, in parallel the adapted clones were tested as described in chapter 
2.0 Section 2.7.7. 
The results are shown in Figure 3.8. From the AQ drug accumulation 
assay (A and B), it was observed that 9C6 and 9C6O were resistant 
compared to the parental strains (positive control). The drug accumulation 
in the 9C6 and 9C6O were lower compared to 47C7, 47C7O, 173D3 and 
173D3O. However, variations were high in each clones, therefore more 
determinations for each clones were needed. These results were not 
consistent with CQ accumulation assay. In the graphs (C and D), 9C6 was not 
resistant for early and late phase while 9C6O were resistant when compared 
to the parental clone, Dd2. On the other hand, 47C7 and 47C7O had lower 
drug accumulation ratio and they were resistant compared to Dd2 while 
173D3 and 173D3O, they were susceptible clones since the drug 
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accumulation ratio were much higher compared to other clones.  However, 
statistically there were no significant difference between the adapted and 
recent clones. Variations in some clones of the  drug accumulation assay 
were high and  this made the phenotype confirmation difficult.   
Further analysis and study should be performed to validate the 
phenotype of the isolated clones from Burkina Faso in order to understand 
the resistance mechanism of AQ resistance
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Figure 3.8 CQ and AQ accumulation in reference strain HB3 and DD2, along with 
adapted clones, 9C6, 47C7, 173D3 and recent clones, 9C6O, 47C7O, 173D3O. A and 
B refer to AQ accumulation at 5 and 20 mins time point in the HB3 and DD2 
parental strains together with adapted and recent clones. While C and D refer to CQ 
accumulation in the HB3 and DD2 parental strains together with adapted and 
recent clones. The data represents the mean value ± SEM of at least three to five 
independent determinations per clone. Significant difference was observed between 
the adapted and recent clones at level *** = p<0.001 using Two Way Anova Test for 
each drug accumulation. 
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3.4.3  Correlations between drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
  
  
 
 
Figure 3.9 Correlation between drugs based on the IC50 values. The IC50  values of all clones 
were tabulated in the graphs to understand the relationship between the drugs. A. Desethyl-
amodiaquine vs Amodiaquine B. Amodiaquine vs Chloroquine C. Desethyl-amodiaquine vs 
Chloroquine  
 
A
D 
B 
C 
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A moderate correlation between AQ and DQ (R2=0.4947) was observed since 
DQ is the main metabolite of AQ and is responsible for the main antimalarial activity 
of the drug. DQ has a longer half time and higher concentration-time profile compared 
to the parent compound (Laurent et al., 1993). A weak positive correlation was 
observed between AQ and CQ (R2=0.3327) in this study, however more data is needed 
to confirm the association between these drugs. Although cross-resistance exists, it 
was not so high in the clonal lines. A significant correlation between CQ and AQ as well 
as DQ is plausible, since resistance to CQ has compromised the efficacy of AQ in the 
field. Nonetheless, positive correlation does not automatically provide any evidence 
for cross-resistance as previously observed for 4-quinolinemethanols mefloquine and 
quinine (Elueze et al., 1996). A few in vitro studies have reported a positive correlation 
between AQ and CQ. Besides that, cross-resistance between DQ and CQ has been 
observed in in vitro P. falciparum isolates from various regions of Africa (Basco et al., 
2003; Ringwald et al., 1998), South America (Childs et al., 1989; Watt et al., 1987) and 
Southeast Asia (Segurado et al., 1987). 
 
3.4.4 Clustering of clonal parasites based on IC50   
A dendrogram is a way to visually describe the relationships between samples, 
genes or isolates. The word dendogram originated from a Greek word dendro means 
"tree" and gramma means "drawing". The tree diagram is frequently used to illustrate 
the arrangement of the clusters produced by hierarchical clustering (Everitt, 1998).  
A cluster analysis was established based on the IC50 values of CQ of 
the clonal lines and classified all isolates into two clusters, A and B. The two 
groups consisted of clonal lines from S173, which were identified previously 
as sensitive clones, and clonal lines of resistance strains from S47 and S9, 
with different level of distribution.  
  Results 
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Figure 3.10  Dendogram of clonal lines from parental clones S9, S47 and S173 produced two 
main cluster, cluster A and B which refers to a sensitive group and resistance group 
respectively. 
 
 All clones from S173 were grouped and closely related to HB3 thus 
indicaing that all clones were sensitive to CQ. From the above cluster, most 
clones of S47 and S9 were closely related; however cluster B showed 
dissimilarities to cluster A. This analysis supported the drug response assay 
and distinguished sensitive or wild-type and resistant strains.  
 
3.5 Dormancy   
The first approach used in finding AQ resistant parasites described in 
the previous section resulted in the isolation of three clones with different 
phenotypes: 9C6, 47C7 and 173D3. Well-characterized isolates are vital to 
study the mechanism of drug resistance. Therefore, more candidate clones 
were needed to achieve the aim of this study. 
Thus, we performed another strategy whereby we challenged the 
field isolates with a certain amount of desethyl-amodiaquine (DQ). The cut-
* 
(A) (B) 
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off value for DQ based on Basco et al., (2002) and WHO (2007) was >60 nM. 
A total of 200 samples from Nouna which were positive by microscopy 
within the study period were selected. The parasites were cultured as 
described in section 2.6.1. Unfortunately, no parasites survived the drug 
concentration used and the cultures were maintained for a maximum two 
months before being discarded. 
Surprisingly, during the in vitro resistance study, after the ring-stage 
parasites were treated with DQ drugs, they developed a round morphology, 
and retained blue cytoplasm and red chromatin, as observed by a thin 
Giemsa smear. We suggested that the parasites with this morphology were 
dormant parasites. Tucker et al., (2012), reported this finding with similar 
morphologies of parasites that were observed by a thin Giemsa smear as 
shown in Figure 3.11 after exposure to artemisinin. 
A preliminary study was performed to confirm the dormancy of 
these parasites using quantitative recrudescence assays. The procedures 
were described in section 2.7.8. Six samples suspected to habour dormant 
parasites shared similar observations as  shown in Figure 3.11. 
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Figure 3.11  Comparison of dormant and dead parasites after a typical exposure to artemisinin 
drugs. (A) After ring-stage parasites were treated with artemisinin drugs, they became 
dormant, developed a rounded morphology, and retained blue cytoplasm and red chromatin 
on a Giemsa smear. (B) Dead or crushed parasites do not have distinct chromatin and 
cytoplasm, appearing globular, and they appeared red/purple on a Giemsa smear (Tucker et 
al., 2012) 
 
  
Figure 3.12  Comparison of suspected dormant and dead parasites after exposure of DQ drug 
in this experiment for culture labelled R12-234 (A) After ring-stage parasites were treated with 
DQ drug, they were suspected to become dormant, formed a rounded shape with  blue 
cytoplasm retained and red chromatin on a Giemsa smear. (B) Globular shaped dead parasites 
observed without distinct cytoplasm and chromatin. 
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As displayed in Figure 3.12, the suspected dormant parasites (A) 
showed different morphologies compared to dead parasites (B). These 
features or morphologies remained unchanged even after the drug was 
taken off from the culture. These parasites were maintained in cultures for a 
maximum two months; however no AQ resistant parasites were recovered 
from after drug challenge. The suspected dormant parasites were assumed 
dead after being challenged with 60 nM DQ and they looked like dormant 
parasites that were challenged by artemisinin. 
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In conclusion, the summary of the findings of this study and characteristics 
of the selected clones that were recorded and hypothesized are listed 
below. 
 
Table 3.4 Summary of the characteristics of selected clones from Nouna 
Burkina Faso based on the genotypic and phenotypic analysis. 
Test  Selected clones 
 Drug 9C6 47C7 173D3 
Genotyping - Resistance Resistance Sensitive 
 CQ Resistance Intermediate 
Resistance 
Sensitive 
Drug response AQ Resistance Sensitive Intermediate 
Resistance 
 DQ Resistance Sensitive Sensitive 
     
Drug CQ Resistance Resistance Sensitive 
Accumulation  AQ Sensitive Sensitive Sensitive 
(Figure 3.6 & 
Figure 3.8) 
CQ Sensitive Resistance Sensitive 
 AQ Resistance Sensitive Sensitive 
  9C6O 47C7O 173D3O 
 CQ Sensitive Resistance Sensitive 
 AQ Resistance Sensitive Sensitive 
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4.0 Discussions 
Bourasso village is situated within the area of the Nouna Health and 
Demographic Health Surveillance System (HDSS), which includes nearly 80,000 
inhabitants under continuous demographic surveillance. This has been used as a 
sample frame for many epidemiological and clinical studies (Kouyate et al., 2008; Louis 
et al., 2012).   In this study, the sampled data showed a decreased parasite prevalence 
during six sampling period from 2000, and between 2009 and 2012. This observation 
supports previous findings in which reduced malaria incidence was also described in 
East African regions such as Tanzania and Kenya (Schellenberg et al., 2004; O’Meara 
et al., 2008; Mmbando et al., 2010). Malaria incidence in Burkina Faso was reported 
by WHO (2011) as still rising and Beiersmann et al., (2011) also reported a reduction 
of parasite prevalence in children less than four years old between the rainy and dry 
seasons from 1999 to 2009 after the increased use of insecticide-treated bed nets 
(ITNs) in the population.  
In parallel to this study, Geiger et al., (2012) reported that asymptomatic 
malaria was more common during the dry season (April 2010-2012) perhaps due to a 
reduced abundance of P. falciparum. The features used as identification for 
asymptomatic malaria were axillary body temperature  of < 37.5˚C at presentation 
with no history of fever and Plasmodium infection confirmed by positive microscopy. 
In contrast, symptomatic malaria was more frequent during the rainy season with a 
high parasite density (>1000 ul/parasites) and it was observed that single and mixed 
infection with P. malariae declined significantly during the study period. A similar 
trend was reported in Malawi, where higher P. falciparum was link to higher 
prevalence of minority species (Bruce, 2008) and another study in Burkina Faso 
showed that the implementation of ITNs has reduced the prevalence of P.malariae 
significantly more than P. falciparum (Hableutzel et al., 1999). 
 Parasite prevalence of P. malariae during the dry season in April was very low 
(<1000 parasites/ul) and a similar observation was reported in another study 
conducted 230km in the south of Burkina Faso, near Bobo-Dioulasso, where P. 
malariae infection was reduced by half during the dry season compared to the rainy 
season (Boudin et al., 1999).  P. ovale infection was very uncommon and only 
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restricted to high-transmission of malaria during the monsoon season. P. malariae 
may not be as terminal as other Plasmodium species but it can cause chronic infection 
by remain in the human host at a low level for an extended period of time (Mohapatra 
et al. 2008; Collin et al., 2007). This could possibly lead to an underestimation of the 
parasite burden, as the detection limit is low for microscopy. The use of molecular 
tools such as PCR in this study was more more sensitive in detecting low levels of other 
Plasmodium species, such as P. malariae and P. ovale.  
Serum samples from patients were analysed for AQ and DQ concentrations. 
Liquid chromatography has been known to have precision and accuracy in determining 
the major metabolites of AQ and DQ when administered to patients with 
uncomplicated malaria (Adedeji et al. 2015). Determination of AQ and DQ 
concentration in the serum was important to determine the resistant parasites. The 
methodology was established by the Department of Pharmacology/Epidemiology, 
University Hospital of Heidelberg.  Optimization was accomplished by monitoring 
varying chromatographic conditions in terms of chromatographic columns, mobile 
phase systems, extraction solvents and solvent for reconstitution before producing an 
appropriate condition that gave satisfactory results. It is crucial to use the correct 
mobile phase used during analysis to obtain good resolution between the peaks and 
to produce analytes with clear sharp peaks, without interference from endogenous 
substances (Adedeji et al. 2015). The mobile phase was capable of separating the IS 
and analytes within 6.0 min, with the UV absorption spectrum set at 340nm. 2(7-
Isoquinolinyl)-Ethanol was selected as the IS because it did not interfere with the 
analytes. The retention times of the drugs on the chromatogram were 4.5 min for IS, 
5.7 min for DQ and 7.6 min for AQ.  
Cultivation of the field isolates was a tedious and laborious task (Basco, 2007). 
Field isolates could appear as early as two days after thawing or as late as 4 weeks. 
Some field isolates took longer to adapt to the culture condition and reproduce. Field 
isolate cultures , which were negative for parasite, after 8 weeks were discarded. 
Pyrosequencing is a reliable technique to determine short DNA sequences. 
However, errors can also occur. In a parallel study by C. Geiger in our laboratory, her 
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data showed parental clones S256, sequenced from cDNA was a sensitive strain.  This 
supports the drug susceptibility assay in Figure 3.2, which has the value of 31.99 ± 
3.71nM against CQ and 9.74±1.49nM against AQ. However, the genotypic analysis 
using pyrosequencing showed, that S256 harbours a CVIET pfcrt haplotype, which is a 
hallmark of a resistant strain (Table 3.2). 
Variation in IC50 values or in vitro assays has been reported (Nzila, 2010) due 
to interlaboratory (interassay) variation when producing either IC50 or IC90. Several 
aspects or conditions could affect the test during parasite cultivation, such as initial 
parasitemia, haematocrit, incubation time, serum and gas mixture composition. A 
right shift in the drug response curve can only be accepted if all the in vitro variables 
remain constant and no interassay variation is present. A universally accepted or 
standard protocol for the in vitro sensitivity assay needs to be established to allow 
comparison of results between different laboratories possible  
Table 4.0 Thresholds used to define in vitro resistance of Plasmodium falciparum to 
amodiaquine  
Threshold Method Reference 
IC50 ≥ 4 nM Isotopic Chaparro & Wasserman 1999 
IC50 ≥ 30 nM Schizont maturation Childs et al. 1989 
IC50 ≥ 59 nM Isotopic Basco et al. 2002 
 
IC50 ≥ 60 nM Isotopic Reynes et al. 1997 
IC50 ≥ 80 nM Isotopic Pradines et al. 1998,  
  Rason et al., 2002 
 Schizont maturation Ringwald et al. 1996 
IC50 ≥ 400 nM Schizont maturation Segurado et al. 1997 
MIC ≥ 4 nM of blood Schizont maturation Draper et al. 1988 
IC90 ≥ 400 nM of blood in  
non immune-populations 
Schizont maturation Wernsdorfer & Paine 1988 
IC99 ≥ 400 nM of blood in  
immune population 
Schizont maturation Wernsdorfer & Paine 1988 
 
Three different phenotypes of P. falciparum (S9, S47, S173) based on the IC50 
values were cultured and the clonal lines were obtained. All clones from S9 and S47 
harboured pfcrt CVIET haplotypes, while all clones from S173 were CVMNK haplotype. 
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The clones from S9 showed higher IC50 values on average against CQ and AQ compared 
to clonal parasites of S47. While some clones were sensitive to DQ for S9 and all were 
sensitive in clonal lines of sample 47. Clonal parasites from S173 had lower IC50 values 
against CQ. Responses to CQ, AQ and DQ varied between the clones, perhaps due to 
the difference in genetic background.  
Clear cross-resistance between CQ and AQ was observed in clonal lines S9 eg 
9C9, 9C7, 9H8 and in clone S47E8. Cross-resistance was detected, however it was not 
high in the clonal lines. CQ and AQ are structurally quite similar, with the main 
difference, being that AQ has a phenolic substitution in the side chain, we expect some 
degree of cross-resistance. Nevertheless, studies of cross-resistance between CQ and 
AQ in vitro have been inadequate; a few studies have revealed cross-resistance 
between the two drugs (Scott et al., Geary et al., 1987), but others have not shown 
any cross-resistance (Geary et al., 1983). In vitro analysis of cross-resistance between 
drugs is essential to prevent the development of introduction of new drugs that are 
already resistant in the field (Fall et al., 2016). 
Antimalarial drug susceptibility and resistance to QN, AQ, piperaquine, and 
lumefantrine are influence by variation in the PfCRT protein. CQ shows cross-
resistance with AQ and QN, which is primarily mediated by K76T mutation. Mutations 
at 72–76 codons at PfCRT confer higher resistance against CQ and medium level of 
resistance against AQ in Southeast Asia and Africa. However, these mutations are 
associated with greater AQ resistance in South America. Therefore, not only is the 
K76T mutation in the  PfCRT protein is an effective molecular marker for the 
antimalarial drug,  their previous usage in the region should also be taken into account 
(Sa et al., 2009). 
AQ resistance was observed in S9 clones where the IC50 values were 
lower than the parental clone. Nevertheless, consistent results of the 
phenotypic analysis need to be obtained for validation. Adaptation to 
laboratory conditions can occur in resistant parasite strains and they can 
lose their resistant phenotype (Nzila et al., 2010).  Long term and continuous 
culture is not recommended for drug testing due to the instability of the 
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resistance phenotype. Unstable phenotypes may be associated with 
reduced parasite fitness, meaning once drug pressure was removed, the 
phenotype reverts back to normal (Nzila et al., 2010). Another study by 
Basco (2006) reported adaptation to goat serum for long term cultivation, 
and different batches of goat sera were responsible for the conflict between 
the obtained results. Nevertheless, more independent determinations are 
required for accurate results and to validate these observations. 
AQ resistance was intensely observed in certain regions (Mandi et al., 2008), 
including North-Western Burkina Faso (Danquah et al., 2010) which then may 
endanger the efficacy of AQ-artesunate treatment regime. As mentioned previously, 
DQ, the main metabolite of AQ, plays a major role in the antimalarial activity of the 
drug. This is due to the higher concentration-time profile and the longer half-life of DQ 
compared to those of the parent compound, AQ (Laurent et al., 1993).  
An increase in DQ resistance, measured using  vitro susceptibly assays was also 
discovered in Dakar, Senegal where the number of resistant cases rose from 5.6% in 
2013 to 30.6% in 2014, (Fall et al., 2014). To date, the AQ-AS is the world’s second 
most widely used artemisinin-based combination therapy (ACT) (Zwang et al., 2009). 
Many previous studies reported on the genetic linkage between  CQ resistance 
and pfcrt in the HB3 ¥ Dd2 cross (Wellems et al., 1991; Fidock et al., 2000; Sa et al., 
2009; Patel et al., 2010). Sanchez et al., (2011) stated that the progeny,  which 
accumulated higher drug levels - showed lower IC50 values, but the progeny that 
accumulated less chloroquine tend to, but does not necessarily always have higher 
IC50 values. Previous studies on CQ resistance suggested a reciprocal correlation 
between susceptibility and drug accumulation in P. falciparum (Fitch, 1970; 1973). 
Polymorphisms within pfmdr1 did not significantly affect susceptibility to or 
accumulation of AQ. PfMDR1 mutations at the N86Y and N1042D positions have been 
shown to be associated with AQ resistance (Sa et al., 2009). K76T and A220S mutations 
in the pfcrt  gene and a N86Y mutation in the pfmdr1 gene are associated with high 
resistance to CQ in field isolates.   
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pfcrt and pfmdr1 are mutated genes in P. falciparum that respond to selection 
by quinoline antimalarial drugs (Fidock et al., 2000; Sa et al., 2009; Sanchez et al., 2010; 
Okombo et al., 2011). These two genes encode proteins of the parasite’s digestive 
vacuolar membrane. The mutations are believed to confer resistance to quinolines by 
inhibiting these drugs from accumulating in the digestive vacuole to the 
concentrations required to inhibit endogenous haem detoxification processes (Fitch, 
2004). 
PfCRT and PfMDR1, are most likely to assist the drug movement in opposite 
directions (Sanchez et al., 2010). When mutated PfCRT functions either as a carrier 
(Sanchez et al., 2004; Summers and Martin, 2010) or as a voltage gated channel of 
drugs (Bray et al., 1996; Paguio et al., 2009), facilitating the efflux of these drugs from 
the digestive vacuole. On the other hand, PfMDR1 seems to act as a drug importer, 
substitution of polymorphic amino acids reduces the ability of PfMDR1 to transport a 
given drug into and therefore concentrates it in the digestive vacuole (Rohrbach et al., 
2006; Sanchez et al., 2008a). 
Interaction between PfCRT and PfMDR1  in a resistant phenotype is not fully 
understood. Several different pfcrt and pfmdr1 alleles have emerged in P. falciparum 
strains in different geographic settings, which makes it complicated to understand 
their relationship. These different polymorphic forms are caused by independent 
founding events and seems to reflect distinct solutions to regional histories of drug 
use and hence drug selection (Sa et al., 2009; Wellems et al., 2009). pfcrt and pfmdr1 
alleles from South America have arisen in an area where AQ use has preceded that of 
chloroquine (Sa et al., 2009). 
In this study, there was a moderate correlation between AQ and DQ (r2=0.495) 
and a weaker correlation between AQ and CQ (r2= 0.333). Bray et al., (1996) found 
that the susceptibility or AQ strains was correlated to the susceptibility of CQ (r2= 0.96) 
and there was a correlation between the accumulation of AQ with accumulation of CQ 
(r2= 0.94). Accumulation of both AQ and CQ resistance was significantly reduced in CQ 
resistant isolates. From the results of the genotyping and drug response tests that 
were performed in this study, we concluded that 9C6 was resistant to CQ, AQ and DQ, 
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47C7 showed an intermediate resistant to CQ, sensitive to AQ and DQ while 173D3 
was sensitive to CQ and DQ, and intermediate resistance to AQ.  Additionally, in the 
drug accumulation test, the results were not consistent with the drug response test 
especially for 9C6/9C6O, while 47C7/47C7O were resistant to CQ and sensitive to AQ 
whereas 173D3 was sensitive to both CQ and AQ.          
Selection of AQ-resistant parasites was unsuccessful in the in vitro selection 
strategy challenged with 60 nM DQ. One of the reason could be that there was no 
resistant strains in the samples collected, or the number of AQ-parasites in the 
population was still very low. Another reason might be that the drug concentration 
used during the challenge was too high. 60 nM of DQ was the cut-off value used as 
suggested by Basco et al., (2002) and WHO (2007). The method used to determine IC50 
in our laboratory was by Sybr Green1 while Basco et al., (2002) was using an isotopic 
method (Table 4.0). This interlaboratory variation could contribute to the discrepancy 
in cut off value to determine AQ resistance (Basco et al., 2004; Briolant et al., 2007). 
An alternative approach to select for AQ resistant parasites is by culturing susceptible 
parasites in vitro with continuous exposure to increasing sublethal drug 
concentrations (Lambros et al., 1984; Odoula et al., 1988). 
In this study, while performing in vitro selection using DQ, the parasites 
exhibited a morphology similar to ART dormant parasites. They were assumed to enter 
the dormancy state after treatment with DQ. After further investigation, there was no 
recrudescence observed after the drug was removed. Dormant parasites were 
reported to be frequently associated with artemisinin-derivates (ART) monotherapy 
treatment (Meshnick et al., 1996). One plausible reason for the failure of ART 
monotherapy was related to the ART-induced dormancy phenomenon (Teuscher et 
al., 2010; Witkowski et al., 2010, Codd et al., 2011), in which ART-treated ring-stage 
parasites undergo growth arrest and manage to survive and appear again when the 
drug was removed or decreased (LaCrue et al., 2011; Tucker et al, 2012). In a dormancy 
state, the metabolic activities were still maintained in the apicoplast and 
mitochondria, despite a general down-regulation in transcription of gene encoding 
important enzymes in numerous metabolic pathways (Chen et al., 2014; Peatey et al., 
2015). The mechanism of ART-induced dormancy is not yet understood but seems to 
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be similar to cell cycle arrest in a mammalian cell. The cell cycle regulators such as 
CDKs and cyclins could play a major role in parasites entering and leaving dormancy.   
Gray et al., (1996) hypothesize that after the exposure to DHA, there was an 
up-regulation of PfCRK1 and PfCRK4 to arrest the development of the cells at G1 
phase. Parasites also decrease the transcription and expression of PfMRK genes and 
other CDKs to prevent the initiation of DNA replication and, later, the parasites fail to 
make a transition from G1 to S phase. Parasites arrested at the G1 phase and stayed 
dormant for a few weeks until the pressure is removed. The data obtained suggests a 
new antimalarial drug target and also a molecular marker for dormant parasites. This 
is a significant finding in the understanding of the mechanism of DHA-induced 
dormancy and open new prospects to avoid recrudescence following artemisinin 
treatment.
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5.0 Outlook 
To date, malaria parasites have developed resistance towards most 
antimalarial drugs. This includes artemisinin derivates in Cambodia (White, 2008), 
which poses a threat to artemisinin-based combination therapy (ACT).  Selecting and 
tracking resistant parasites from field isolates is difficult, challenging and time 
consuming, although it can provide critical and useful information on the genetic basis 
of drug resistance. Such information can help to predict, anticipate and control the 
spread of resistance. For example, discovery of the gene pfmdr1 which confers 
mefloquine resistance resulted from in vitro studies (Nzila, 2010). 
To study the mechanisms of resistance, we need to find well-characterized 
drug-resistant strains. However, such strains are not accessible for most antimalarial 
drugs. Rodent malaria models such as Plasmodium chabaudi, Plasmodium yeolii, 
Plasmodium berghei and Plasmodium vinkei have been used extensively as 
alternatives to study drug resistance in vivo and aid selection of drug-resistant parasite 
lines for drug mechanisms research (Peters, 1987). Murine models can have 
limitations, since mechanisms of CQ and artemisinin resistance may differ compared 
with P. falciparum (Hunt 2007). 
  Several strategies and methods could be improved for future studies to select 
for AQ-resistant parasites. In vitro selection strategies are another potential approach 
but the time taken to produce the resistant strain is very long and slow. The risk of 
contamination and slow parasites growth limits the effort in selecting resistant 
parasites. Increasing the concentration of DQ in in vitro selection strategy might 
introduce additional mutations with time and the underlying mechanism of AQ 
resistance could be resolved. Thus, in the absence of a well-characterized drug-
resistant strains, the mechanism of AQ resistance still awaits to be characterized. 
In this study, three different clones were characterized using two response 
parameters and genotyping as discussed in the previous chapters. Further 
investigations to validate the phenotype are required.  Many classes of compounds 
have been identified to reverse CQ resistance or re-sensitize to CQ sensitive levels such 
as verapamil. This is a CQ chemo sensitizer and a blocker for PfCRT (Henry et al., 2006, 
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Sanchez et al., 2004). Reversibility testing using verapamil could be used to confirm 
the isolated resistant strains. 
Tracking or selecting AQ-resistant parasites could be achieved by several 
means, such as by increasing the sample size to increase the probability of finding the 
phenotype of interest. As mentioned above, the task is very laborious and time 
consuming, hampered by the slow growth of parasites and potential risk of culture 
contamination. Highly trained personnel, well-equipped laboratory facilities and 
financial investment would be required. Previous studies have reported, 
understanding the relationship between pfcrt and pfmdr1 regarding resistance is 
partly understood.  Several different pfcrt and pfmdr1 alleles have emerged in P. 
falciparum strains in different geographic settings (Sa et al., 2009; Wellems et al., 
2009). Using this evidence, the samples used for tracking AQ-resistant parasites 
should come from several different regions with different histories of drug use, such 
as South America, Asia and Oceania. 
Both drug response parameters, in vitro susceptibility and drug uptake are vital 
tools to measure parasite response to drugs. Replicates or several independent 
determinations of each experiments are essential to obtain accurate results and 
reduce variations. In this study, it is recommended to perform five to six independent 
determinations for each experiment. Unstable resistant clones can lose their 
phenotype if continuously cultivated for a very long period and become culture-
adapted parasites. To avoid losing resistant parasites, using freshly cultured clones 
and performing the assays after two cycles is recommended.  
Different laboratories used different protocols for in vitro drug sensitivity 
assays and a universally-accepted protocol is not available. The need for a 
standardized assay to allow data comparison between laboratories should be 
considered. To overcome this situation, a researcher should choose one protocol that 
best satisfies his or her needs. After the choice is made, it is necessary to establish and 
maintain the protocol over time so that important findings can be deduced such as 
trends and the emergence of drug resistant isolates (Basco, 2007). 
  Outlook 
88 
 
Conventionally, classical linkage mapping has been using genetic 
crosses to examine the patterns of drug resistance phenotypes. Later 
technology, such as whole genome sequencing (WGS) has provided a 
powerful alternative to study drug resistance and may generate a few 
numbers of candidate gene regions involved in drug resistance. If such a 
study obtained clear and well-characterized AQ-resistant clone, WGS would 
be another choice to determine genes responsible for the AQ resistance
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7.0  Appendices 
Appendix 1.0 Stages in the life cycle of Plasmodium falciparum (Illustration: Coatney 
GR, Collins WE, Warren M, Contacos PG (1971) The primate malarias. (Bethesda): U.S. 
Department of Health, Education and Welfare.) 
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Appendix 2.0 Standard Calibration for Amodiaquine 
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Appendix 3.0 Standard Calibration for Desethyl-Amodiaquine 
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Appendix 4.0  Antimalarial drugs used as monotherapy (Modified from Antony et al.,2016) 
 
Antimalarial 
derivaties 
Chemical Family Drug Name Half Life Mechanism of Action Used Contraindictions Status of 
Resistance 
Genetic Markers 
of Drug 
Resistance 
Quinoline 
derivates 
4-Aminoquinolines Chloroquine 
(CQ) 
41±14 
days 
Accumulate in the digestive 
vacuole of the parasite 
 
Inhibition of heme 
detoxification 
Treatment of non-
falciparum infections 
 
Treatment of 
falciparum infections 
where CQ remains 
sensitive 
chemoprophylaxis in 
regions where CQ 
remains sensitive 
 
- Yes Point mutation in 
Pfcrt, Pfmdr1, 
Pfmrp 
  Amodiaquine 
(AQ) 
5 hrs Accumulate in the digestive 
vacuole of parasite 
 
Inhibition of heme 
detoxification 
Treatment of non-
severe falciparum 
infections where CQ 
resistance has emerged 
- Yes Point mutation 
and copy number 
variation in 
Pfmdr1 
 Amino Alchohols Quinine 10-12 
hrs 
Accumulate in the digestive 
vacuole of parasite 
 
 
 
Inhibition of heme 
detoxification 
Treatment of severe 
malaria and multidrug-
resistance falciparum 
infections 
 
Treatment of malaria 
during pregnancy in the 
1st trimester 
- Yes Point mutation in 
Pfmdr1, Pfmrp, 
Pfnhe1 and copy 
number variation 
in Pfmdr1 
  Mefloquine 14-18 
days 
Accumulate in the digestive 
vacuole of parasite 
 
 
 
 
Treatment of non-
severe falciparum 
infections where CQ 
and SP resistance has 
emerged 
 
Known/ suspected 
history of 
neuropsychiatric 
disorder 
 
 
Yes Point mutation 
and copy number 
variation in 
Pfmdr1 
   
108 
 
Inhibition of heme 
detoxification 
 
Chemoprophylaxis in 
regions with CQ 
resistance 
History of seizures 
  Halofantrine 10-90 
hrs 
Accumulate in the digestive 
vacuole of parasite 
 
 
 
 
Inhibition of heme 
detoxification 
 
Treatment of suspected 
multidrug-resistant 
falciparum malaria 
infections 
Concomitant use of 
Halofantrine 
 
Preexisting cardiac 
disease 
 
Congenital 
prolongation of QTc 
interval 
 
Treatment of 
mefloquine within 
three weeks prior 
use 
 
Pregnancy 
Yes Point mutation 
and copy number 
variation in 
Pfmdr1 
  Lumefantrine 3-6 days Accumulate in the digestive 
vacuole of parasite 
 
 
 
 
Inhibition of heme 
detoxification 
Treatment of non-
severe falciparum 
infections where CQ 
and SP resistance has 
emerged 
 Yes Point mutation 
and copy number 
variation in 
Pfmdr1 
 8-Aminoquinolines Primaquine 6 hrs Not precisely known Treatment of vivax and 
ovale infections to 
prevent relapse  
 
Gametocytodical agent 
 
G6PD deficiency 
 
 
 
Pregnancy 
Yes Not known 
 Naphtoquinone Atovaquone 59 hrs Targets the cytochrome bc1 
complex, located in the inner 
Treatment of 
multidrug-resistant 
 Yes Point mutation in 
cytb gene 
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mitochondrial membrane of 
parasite 
 
Inhibits the respiratory reaction 
of parasite 
falciparum malaria 
infections 
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Appendix 5.0  Analysis of Variance 
 
1. Lab Strains vs Field Isolates_2009 
 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   IC50   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 129418.969a 21 6162.808 18.208 .000 
Intercept 115762.857 1 115762.857 342.030 .000 
Drug 49873.632 1 49873.632 147.355 .000 
Clones 34652.638 10 3465.264 10.238 .000 
Drug * Clones 26125.874 10 2612.587 7.719 .000 
Error 28430.516 84 338.459   
Total 310191.579 106    
Corrected Total 157849.485 105    
a. R Squared = .820 (Adjusted R Squared = .775) 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   IC50   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 129418.969a 21 6162.808 18.208 .000 
Intercept 115762.857 1 115762.857 342.030 .000 
Drug 49873.632 1 49873.632 147.355 .000 
Clones 34652.638 10 3465.264 10.238 .000 
Drug * Clones 26125.874 10 2612.587 7.719 .000 
Error 28430.516 84 338.459   
Total 310191.579 106    
Corrected Total 157849.485 105    
a. R Squared = .820 (Adjusted R Squared = .775) 
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Post Hoc Tests 
 
Clones 
 
Multiple Comparisons 
Dependent Variable:   IC50   
Tukey HSD   
(I) Clones (J) Clones 
Mean Difference 
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
Dd2 GB4 -10.4221 8.51627 .978 -48.8537 28.0094 
HB3 55.5782* 7.41246 .000 22.1279 89.0286 
S16 40.6574* 7.61718 .000 6.2832 75.0316 
S17 47.5031* 8.97694 .000 6.9927 88.0135 
S25 46.7693* 6.95350 .000 15.3901 78.1485 
S27 53.0593* 8.51627 .000 14.6277 91.4908 
S47 28.5694 7.61718 .014 -5.8048 62.9436 
S6 11.8487 7.86016 .913 -23.6221 47.3194 
S79 43.9677* 8.15371 .000 7.1723 80.7631 
S9 15.0714 7.61718 .664 -19.3028 49.4456 
GB4 Dd2 10.4221 8.51627 .978 -28.0094 48.8537 
HB3 66.0004* 8.89495 .000 25.8599 106.1408 
S16 51.0796* 9.06626 .000 10.1661 91.9931 
S17 57.9252* 10.23528 .000 11.7363 104.1142 
S25 57.1914* 8.51627 .000 18.7599 95.6230 
S27 63.4814* 9.83374 .000 19.1045 107.8584 
S47 38.9916 9.06626 .002 -1.9219 79.9051 
S6 22.2708 9.27134 .378 -19.5682 64.1098 
S79 54.3898* 9.52148 .000 11.4220 97.3576 
S9 25.4936 9.06626 .172 -15.4199 66.4071 
HB3 Dd2 -55.5782* 7.41246 .000 -89.0286 -22.1279 
GB4 -66.0004* 8.89495 .000 -106.1408 -25.8599 
S16 -14.9208 8.03833 .743 -51.1956 21.3539 
S17 -8.0752 9.33695 .999 -50.2102 34.0599 
S25 -8.8090 7.41246 .982 -42.2593 24.6414 
S27 -2.5190 8.89495 1.000 -42.6594 37.6215 
S47 -27.0088 8.03833 .043 -63.2836 9.2659 
S6 -43.7296* 8.26895 .000 -81.0450 -6.4141 
S79 -11.6106 8.54847 .955 -50.1874 26.9663 
S9 -40.5068* 8.03833 .000 -76.7816 -4.2321 
S16 Dd2 -40.6574* 7.61718 .000 -75.0316 -6.2832 
GB4 -51.0796* 9.06626 .000 -91.9931 -10.1661 
  Appendices 
112 
 
HB3 14.9208 8.03833 .743 -21.3539 51.1956 
S17 6.8457 9.50030 1.000 -36.0265 49.7179 
S25 6.1119 7.61718 .999 -28.2624 40.4861 
S27 12.4019 9.06626 .953 -28.5116 53.3154 
S47 -12.0880 8.22750 .926 -49.2164 25.0404 
S6 -28.8088 8.45295 .038 -66.9546 9.3370 
S79 3.3102 8.72658 1.000 -36.0704 42.6909 
S9 -25.5860 8.22750 .085 -62.7144 11.5424 
S17 Dd2 -47.5031* 8.97694 .000 -88.0135 -6.9927 
GB4 -57.9252* 10.23528 .000 -104.1142 -11.7363 
HB3 8.0752 9.33695 .999 -34.0599 50.2102 
S16 -6.8457 9.50030 1.000 -49.7179 36.0265 
S25 -.7338 8.97694 1.000 -41.2442 39.7766 
S27 5.5562 10.23528 1.000 -40.6328 51.7452 
S47 -18.9337 9.50030 .654 -61.8059 23.9385 
S6 -35.6544 9.69620 .017 -79.4107 8.1018 
S79 -3.5354 9.93565 1.000 -48.3722 41.3014 
S9 -32.4317 9.50030 .037 -75.3039 10.4405 
S25 Dd2 -46.7693* 6.95350 .000 -78.1485 -15.3901 
GB4 -57.1914* 8.51627 .000 -95.6230 -18.7599 
HB3 8.8090 7.41246 .982 -24.6414 42.2593 
S16 -6.1119 7.61718 .999 -40.4861 28.2624 
S17 .7338 8.97694 1.000 -39.7766 41.2442 
S27 6.2900 8.51627 1.000 -32.1415 44.7215 
S47 -18.1999 7.61718 .386 -52.5741 16.1744 
S6 -34.9206 7.86016 .001 -70.3913 .5501 
S79 -2.8016 8.15371 1.000 -39.5970 33.9938 
S9 -31.6979 7.61718 .003 -66.0721 2.6764 
S27 Dd2 -53.0593* 8.51627 .000 -91.4908 -14.6277 
GB4 -63.4814* 9.83374 .000 -107.8584 -19.1045 
HB3 2.5190 8.89495 1.000 -37.6215 42.6594 
S16 -12.4019 9.06626 .953 -53.3154 28.5116 
S17 -5.5562 10.23528 1.000 -51.7452 40.6328 
S25 -6.2900 8.51627 1.000 -44.7215 32.1415 
S47 -24.4899 9.06626 .217 -65.4034 16.4236 
S6 -41.2106 9.27134 .001 -83.0496 .6283 
S79 -9.0916 9.52148 .997 -52.0594 33.8762 
S9 -37.9879 9.06626 .003 -78.9014 2.9256 
S47 Dd2 -28.5694 7.61718 .014 -62.9436 5.8048 
GB4 -38.9916 9.06626 .002 -79.9051 1.9219 
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HB3 27.0088 8.03833 .043 -9.2659 63.2836 
S16 12.0880 8.22750 .926 -25.0404 49.2164 
S17 18.9337 9.50030 .654 -23.9385 61.8059 
S25 18.1999 7.61718 .386 -16.1744 52.5741 
S27 24.4899 9.06626 .217 -16.4236 65.4034 
S6 -16.7208 8.45295 .664 -54.8666 21.4250 
S79 15.3982 8.72658 .797 -23.9824 54.7789 
S9 -13.4980 8.22750 .860 -50.6264 23.6304 
S6 Dd2 -11.8487 7.86016 .913 -47.3194 23.6221 
GB4 -22.2708 9.27134 .378 -64.1098 19.5682 
HB3 43.7296* 8.26895 .000 6.4141 81.0450 
S16 28.8088 8.45295 .038 -9.3370 66.9546 
S17 35.6544 9.69620 .017 -8.1018 79.4107 
S25 34.9206 7.86016 .001 -.5501 70.3913 
S27 41.2106 9.27134 .001 -.6283 83.0496 
S47 16.7208 8.45295 .664 -21.4250 54.8666 
S79 32.1190 8.93945 .022 -8.2222 72.4603 
S9 3.2228 8.45295 1.000 -34.9230 41.3686 
S79 Dd2 -43.9677* 8.15371 .000 -80.7631 -7.1723 
GB4 -54.3898* 9.52148 .000 -97.3576 -11.4220 
HB3 11.6106 8.54847 .955 -26.9663 50.1874 
S16 -3.3102 8.72658 1.000 -42.6909 36.0704 
S17 3.5354 9.93565 1.000 -41.3014 48.3722 
S25 2.8016 8.15371 1.000 -33.9938 39.5970 
S27 9.0916 9.52148 .997 -33.8762 52.0594 
S47 -15.3982 8.72658 .797 -54.7789 23.9824 
S6 -32.1190 8.93945 .022 -72.4603 8.2222 
S9 -28.8962 8.72658 .050 -68.2769 10.4844 
S9 Dd2 -15.0714 7.61718 .664 -49.4456 19.3028 
GB4 -25.4936 9.06626 .172 -66.4071 15.4199 
HB3 40.5068* 8.03833 .000 4.2321 76.7816 
S16 25.5860 8.22750 .085 -11.5424 62.7144 
S17 32.4317 9.50030 .037 -10.4405 75.3039 
S25 31.6979 7.61718 .003 -2.6764 66.0721 
S27 37.9879 9.06626 .003 -2.9256 78.9014 
S47 13.4980 8.22750 .860 -23.6304 50.6264 
S6 -3.2228 8.45295 1.000 -41.3686 34.9230 
S79 28.8962 8.72658 .050 -10.4844 68.2769 
Based on observed means. 
 The error term is Mean Square(Error) = 338.459. 
*. The mean difference is significant at the .001 level. 
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2. Clone 9C6 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   logIC50   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 24.624a 35 .704 24.497 .000 .913 
Intercept 207.700 1 207.700 7231.901 .000 .989 
Clones 3.598 11 .327 11.390 .000 .604 
Drug 18.246 2 9.123 317.659 .000 .886 
Clones * Drug 1.338 22 .061 2.117 .008 .362 
Error 2.355 82 .029    
Total 260.902 118     
Corrected Total 26.979 117     
a. R Squared = .913 (Adjusted R Squared = .875) 
 
 
a. Clones 
 
 
Estimates 
Dependent Variable:   logIC50   
Clones Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
9A4 1.446 .054 1.339 1.554 
9A6 1.316 .056 1.204 1.429 
9C6 1.521 .054 1.413 1.628 
9C9 1.370 .049 1.273 1.467 
9D7 1.368 .069 1.231 1.506 
9E3 1.197 .069 1.059 1.334 
9F1 1.361 .061 1.240 1.482 
9F2 1.508 .049 1.410 1.605 
9H7 1.472 .050 1.373 1.572 
9H8 1.423 .052 1.320 1.525 
Dd2 1.620 .050 1.521 1.720 
HB3 .911 .054 .804 1.019 
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Pairwise Comparisons 
Dependent Variable:   logIC50   
(I) Clones (J) Clones 
Mean Difference 
(I-J) Std. Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
9A4 9A6 .130 .078 .100 -.026 .285 
9C6 -.074 .076 .335 -.226 .078 
9C9 .076 .073 .298 -.069 .222 
9D7 .078 .088 .376 -.097 .253 
9E3 .250* .088 .006 .075 .424 
9F1 .085 .082 .298 -.077 .248 
9F2 -.061 .073 .402 -.206 .084 
9H7 -.026 .074 .725 -.172 .121 
9H8 .024 .075 .753 -.125 .172 
Dd2 -.174* .074 .021 -.320 -.027 
HB3 .535* .076 .000 .383 .687 
9A6 9A4 -.130 .078 .100 -.285 .026 
9C6 -.204* .078 .011 -.360 -.049 
9C9 -.053 .075 .476 -.202 .095 
9D7 -.052 .089 .564 -.229 .126 
9E3 .120 .089 .184 -.058 .297 
9F1 -.045 .083 .594 -.210 .121 
9F2 -.191* .075 .012 -.340 -.043 
9H7 -.156* .075 .042 -.306 -.006 
9H8 -.106 .076 .168 -.259 .046 
Dd2 -.304* .075 .000 -.454 -.154 
HB3 .405* .078 .000 .249 .561 
9C6 9A4 .074 .076 .335 -.078 .226 
9A6 .204* .078 .011 .049 .360 
9C9 .151* .073 .042 .006 .296 
9D7 .152 .088 .087 -.022 .327 
9E3 .324* .088 .000 .149 .498 
9F1 .160 .082 .054 -.003 .322 
9F2 .013 .073 .861 -.132 .158 
9H7 .048 .074 .515 -.098 .195 
9H8 .098 .075 .195 -.051 .246 
Dd2 -.100 .074 .180 -.246 .047 
HB3 .609* .076 .000 .457 .761 
9C9 9A4 -.076 .073 .298 -.222 .069 
9A6 .053 .075 .476 -.095 .202 
9C6 -.151* .073 .042 -.296 -.006 
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9D7 .002 .085 .984 -.167 .170 
9E3 .173* .085 .044 .005 .342 
9F1 .009 .078 .909 -.147 .165 
9F2 -.138* .069 .050 -.275 .000 
9H7 -.102 .070 .147 -.242 .037 
9H8 -.053 .071 .459 -.194 .089 
Dd2 -.250* .070 .001 -.389 -.111 
HB3 .458* .073 .000 .313 .604 
9D7 9A4 -.078 .088 .376 -.253 .097 
9A6 .052 .089 .564 -.126 .229 
9C6 -.152 .088 .087 -.327 .022 
9C9 -.002 .085 .984 -.170 .167 
9E3 .171 .098 .084 -.023 .366 
9F1 .007 .092 .938 -.176 .191 
9F2 -.140 .085 .103 -.308 .029 
9H7 -.104 .085 .226 -.274 .066 
9H8 -.055 .086 .528 -.226 .117 
Dd2 -.252* .085 .004 -.422 -.082 
HB3 .457* .088 .000 .282 .631 
9E3 9A4 -.250* .088 .006 -.424 -.075 
9A6 -.120 .089 .184 -.297 .058 
9C6 -.324* .088 .000 -.498 -.149 
9C9 -.173* .085 .044 -.342 -.005 
9D7 -.171 .098 .084 -.366 .023 
9F1 -.164 .092 .079 -.348 .019 
9F2 -.311* .085 .000 -.479 -.142 
9H7 -.275* .085 .002 -.445 -.106 
9H8 -.226* .086 .011 -.398 -.054 
Dd2 -.423* .085 .000 -.593 -.254 
HB3 .285* .088 .002 .111 .460 
9F1 9A4 -.085 .082 .298 -.248 .077 
9A6 .045 .083 .594 -.121 .210 
9C6 -.160 .082 .054 -.322 .003 
9C9 -.009 .078 .909 -.165 .147 
9D7 -.007 .092 .938 -.191 .176 
9E3 .164 .092 .079 -.019 .348 
9F2 -.147 .078 .064 -.302 .009 
9H7 -.111 .079 .162 -.268 .046 
9H8 -.062 .080 .441 -.221 .097 
Dd2 -.259* .079 .001 -.416 -.102 
HB3 .449* .082 .000 .287 .612 
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9F2 9A4 .061 .073 .402 -.084 .206 
9A6 .191* .075 .012 .043 .340 
9C6 -.013 .073 .861 -.158 .132 
9C9 .138* .069 .050 .000 .275 
9D7 .140 .085 .103 -.029 .308 
9E3 .311* .085 .000 .142 .479 
9F1 .147 .078 .064 -.009 .302 
9H7 .035 .070 .614 -.104 .175 
9H8 .085 .071 .236 -.056 .226 
Dd2 -.112 .070 .112 -.252 .027 
HB3 .596* .073 .000 .451 .741 
9H7 9A4 .026 .074 .725 -.121 .172 
9A6 .156* .075 .042 .006 .306 
9C6 -.048 .074 .515 -.195 .098 
9C9 .102 .070 .147 -.037 .242 
9D7 .104 .085 .226 -.066 .274 
9E3 .275* .085 .002 .106 .445 
9F1 .111 .079 .162 -.046 .268 
9F2 -.035 .070 .614 -.175 .104 
9H8 .050 .072 .493 -.093 .192 
Dd2 -.148* .071 .040 -.289 -.007 
HB3 .561* .074 .000 .414 .707 
9H8 9A4 -.024 .075 .753 -.172 .125 
9A6 .106 .076 .168 -.046 .259 
9C6 -.098 .075 .195 -.246 .051 
9C9 .053 .071 .459 -.089 .194 
9D7 .055 .086 .528 -.117 .226 
9E3 .226* .086 .011 .054 .398 
9F1 .062 .080 .441 -.097 .221 
9F2 -.085 .071 .236 -.226 .056 
9H7 -.050 .072 .493 -.192 .093 
Dd2 -.197* .072 .007 -.340 -.054 
HB3 .511* .075 .000 .363 .660 
Dd2 9A4 .174* .074 .021 .027 .320 
9A6 .304* .075 .000 .154 .454 
9C6 .100 .074 .180 -.047 .246 
9C9 .250* .070 .001 .111 .389 
9D7 .252* .085 .004 .082 .422 
9E3 .423* .085 .000 .254 .593 
9F1 .259* .079 .001 .102 .416 
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9F2 .112 .070 .112 -.027 .252 
9H7 .148* .071 .040 .007 .289 
9H8 .197* .072 .007 .054 .340 
HB3 .709* .074 .000 .562 .855 
HB3 9A4 -.535* .076 .000 -.687 -.383 
9A6 -.405* .078 .000 -.561 -.249 
9C6 -.609* .076 .000 -.761 -.457 
9C9 -.458* .073 .000 -.604 -.313 
9D7 -.457* .088 .000 -.631 -.282 
9E3 -.285* .088 .002 -.460 -.111 
9F1 -.449* .082 .000 -.612 -.287 
9F2 -.596* .073 .000 -.741 -.451 
9H7 -.561* .074 .000 -.707 -.414 
9H8 -.511* .075 .000 -.660 -.363 
Dd2 -.709* .074 .000 -.855 -.562 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
Univariate Tests 
Dependent Variable:   logIC50   
 Sum of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Contrast 3.598 11 .327 11.390 .000 .604 
Error 2.355 82 .029    
The F tests the effect of Clones. This test is based on the linearly independent pairwise comparisons 
among the estimated marginal means. 
 
 
 
b. Drug 
 
Estimates 
Dependent Variable:   logIC50   
Drug Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
AQ 1.163 .028 1.108 1.219 
CQ 1.944 .028 1.889 1.999 
DQ 1.021 .029 .965 1.078 
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Pairwise Comparisons 
Dependent Variable:   logIC50   
(I) Drug (J) Drug 
Mean Difference 
(I-J) Std. Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
AQ CQ -.780* .039 .000 -.858 -.702 
DQ .142* .040 .001 .063 .222 
CQ AQ .780* .039 .000 .702 .858 
DQ .922* .040 .000 .843 1.001 
DQ AQ -.142* .040 .001 -.222 -.063 
CQ -.922* .040 .000 -1.001 -.843 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments). 
 
 
Univariate Tests 
Dependent Variable:   logIC50   
 Sum of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Contrast 18.246 2 9.123 317.659 .000 .886 
Error 2.355 82 .029    
The F tests the effect of Drug. This test is based on the linearly independent pairwise comparisons 
among the estimated marginal means. 
 
3. Drug Accumulation Assay 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Accu   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 19502845.251a 19 1026465.540 6.738 .000 
Intercept 32821536.932 1 32821536.932 215.457 .000 
Clone 8401879.161 4 2100469.790 13.789 .000 
Time 4287480.336 3 1429160.112 9.382 .000 
Clone * Time 5793017.251 12 482751.438 3.169 .011 
Error 3046686.273 20 152334.314   
Total 56870425.456 40    
Corrected Total 22549531.524 39    
a. R Squared = .865 (Adjusted R Squared = .737) 
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Post Hoc Tests 
 
 
Clone 
 
 
Multiple Comparisons 
Dependent Variable:   Accu   
Tukey HSD   
(I) Clone (J) Clone 
Mean Difference 
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
173D3 47C7 860.4600 195.15014 .002 -69.5589 1790.4788 
9C6 1157.2165* 178.14689 .000 308.2293 2006.2037 
Dd2 1278.2610* 195.15014 .000 348.2422 2208.2799 
HB3 776.8080 239.00914 .029 -362.2278 1915.8438 
47C7 173D3 -860.4600 195.15014 .002 -1790.4788 69.5589 
9C6 296.7565 178.14689 .476 -552.2306 1145.7437 
Dd2 417.8011 195.15014 .242 -512.2178 1347.8199 
HB3 -83.6520 239.00914 .997 -1222.6878 1055.3838 
9C6 173D3 -1157.2165* 178.14689 .000 -2006.2037 -308.2293 
47C7 -296.7565 178.14689 .476 -1145.7437 552.2306 
Dd2 121.0446 178.14689 .959 -727.9426 970.0317 
HB3 -380.4085 225.33998 .463 -1454.3017 693.4848 
Dd2 173D3 -1278.2610* 195.15014 .000 -2208.2799 -348.2422 
47C7 -417.8011 195.15014 .242 -1347.8199 512.2178 
9C6 -121.0446 178.14689 .959 -970.0317 727.9426 
HB3 -501.4530 239.00914 .259 -1640.4888 637.5828 
HB3 173D3 -776.8080 239.00914 .029 -1915.8438 362.2278 
47C7 83.6520 239.00914 .997 -1055.3838 1222.6878 
9C6 380.4085 225.33998 .463 -693.4848 1454.3017 
Dd2 501.4530 239.00914 .259 -637.5828 1640.4888 
Based on observed means. 
 The error term is Mean Square(Error) = 152334.314. 
*. The mean difference is significant at the 0.001 level. 
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Time 
 
Multiple Comparisons 
Dependent Variable:   Accu   
Tukey HSD   
(I) Time (J) Time 
Mean Difference 
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
20AQ 20CQ 705.7401 174.54759 .003 -90.8298 1502.3099 
5AQ 870.3619* 174.54759 .000 73.7920 1666.9318 
5CQ 896.3632* 174.54759 .000 99.7934 1692.9331 
20CQ 20AQ -705.7401 174.54759 .003 -1502.3099 90.8298 
5AQ 164.6218 174.54759 .782 -631.9480 961.1917 
5CQ 190.6232 174.54759 .698 -605.9467 987.1930 
5AQ 20AQ -870.3619* 174.54759 .000 -1666.9318 -73.7920 
20CQ -164.6218 174.54759 .782 -961.1917 631.9480 
5CQ 26.0013 174.54759 .999 -770.5685 822.5712 
5CQ 20AQ -896.3632* 174.54759 .000 -1692.9331 -99.7934 
20CQ -190.6232 174.54759 .698 -987.1930 605.9467 
5AQ -26.0013 174.54759 .999 -822.5712 770.5685 
Based on observed means. 
 The error term is Mean Square(Error) = 152334.314. 
*. The mean difference is significant at the 0.001 level. 
 
 
4. Drug Accumulation Assay (Adapted strains vs Recent strains) 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Uptake   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 2011580.561a 5 402316.112 1.226 .340 
Intercept 12571935.461 1 12571935.461 38.306 .000 
Clone 1217497.230 2 608748.615 1.855 .187 
New_Old 11579.377 1 11579.377 .035 .853 
Clone * New_Old 770575.464 2 385287.732 1.174 .333 
Error 5579418.942 17 328201.114   
Total 20685200.347 23    
Corrected Total 7590999.503 22    
a. R Squared = .265 (Adjusted R Squared = .049) 
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Tests of Normality 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Uptake .268 23 .000 .868 23 .006 
a. Lilliefors Significance Correction 
 
 
b. AQ-20 mins 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Uptake   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 5216954.248a 5 1043390.850 1.519 .231 
Intercept 42265804.042 1 42265804.042 61.519 .000 
New_Old 1587351.566 1 1587351.566 2.310 .145 
Clone 3301111.233 2 1650555.617 2.402 .117 
New_Old * Clone 32952.952 2 16476.476 .024 .976 
Error 13053741.505 19 687039.027   
Total 64032587.021 25    
Corrected Total 18270695.752 24    
a. R Squared = .286 (Adjusted R Squared = .098) 
 
 
 
 
 
 
 
